Patent Grant
12023226
This invention relates to methods and devices for skin tightening or for treating diseases, disorders, and conditions that would benefit from skin restoration or tightening.
Many human health issues arise from the damage or loss of tissue due to disease, advanced age, and/or injury. In aesthetic medicine, elimination of excess tissue and/or skin laxity is an important concern that affects more than 25% of the U.S. population. Conventional surgical therapies (e.g., a face lift, brow lift, or breast lift) can be effective but are often invasive, inconvenient, and expensive, while scarring limits its applicability.
Although minimally invasive methods are available, such methods are generally less effective than surgical methods. Methods using energy sources (e.g., laser, non-coherent light, radiofrequency, or ultrasound) can be effective at improving the architecture and the texture of the skin but are much less effective at tightening the skin or reducing skin laxity. Neurotoxins, such as botulinum toxin, reduce the formation of dynamic wrinkles by paralysis of the injected muscles, but such toxins have minimal or no effect on skin tightness or laxity. Finally, dermal fillers, such as hyaluronic acid, are injected in the dermal layer to smooth out wrinkles and improve contours, but such fillers do not tighten or reduce laxity of the skin. Thus, surgical therapies remain the gold standard for lifting and/or tightening skin, as compared to energy-based techniques (e.g., with laser, radiofrequency, or ultrasound ablation) and injection-based techniques (e.g., with botulinum toxin or hyaluronic acid- or collagen-based fillers).
Accordingly, there is a need for improved methods and devices that increase the effectiveness of minimally-invasive techniques while maintaining convenience, affordability, and/or accessibility to patients requiring tissue restoration.
This invention relates to methods and devices (e.g., a dressing) for the tightening of skin (or the reduction of skin laxity) by selective opening or closing a plurality of small slits or holes (e.g., wounds) formed by incision or excision of tissue portions. For example, tissue excision can be performed by fractional ablation of the epidermal and/or dermal layer of the skin with a hollow coring needle, by fractional laser ablation, by fractional radiofrequency ablation, or by fractional ultrasonic ablation. Various methods and devices are provided to close small wounds, including smart or tunable dressings that allow for titration of the tightening effect after application to the skin of a subject.
Accordingly, the present invention features a tunable dressing including (i) an adhesive layer and (ii) a regulatable layer that includes one or more materials, where exposure of the regulatable layer to one or more external stimuli (e.g., any described herein) results in a change in a physical characteristic (e.g., any described herein) in the one or more materials in at least a portion of the dressing (e.g., including planar or non-planar changes across the entire device or in a portion of the device).
The present invention also features a tunable dressing including (i) an adhesive layer and (ii) an unstretched layer that includes one or more materials, where exposure of the unstretched layer to one or more external stimuli (e.g., any described herein) results in contraction or expansion in one or more directions (e.g., in the x-, y-, z-, xy-, xz-, yz-, and/or xyz-directions) in at least a portion of the area of the dressing. In some embodiments, the contraction or expansion is in the x-axis, y-axis, and/or z-axis of the dressing, as compared to before the exposure (e.g., in the xy-, xz-, yz-, and/or xyz-plane of the dressing, as compared to before the exposure). In further embodiments, the contraction or expansion is uniform or non-uniform.
In some embodiments, the change in a physical characteristic includes an increase in tension of the dressing, a decrease in tension of the dressing, an increase in compressive force exerted by the dressing, a decrease in compressive force exerted by the dressing, compression in one or more directions of the dressing, and/or expansion in one or more directions of the dressing (e.g., where such an increase or decrease is in the x-axis, y-axis, and/or z-axis or in the xy-, xz-, xy-, and/or xyz-plane of the dressing, as compared to before the exposure). In particular embodiments, the increase or decrease in tension or compressive force and/or the expansion or compression of the device is an increase or decrease of intensity of at least about 0.5% after exposure of the one or more external stimuli, as compared to before the exposure (e.g., an increase or decrease of at least about 0.5% (e.g., at least about 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.5%, 1.7%, 2.0%, 2.2%, 2.5%, 2.7%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, 10.5%, 15%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or more) or from about 0.5% to 20%, 20% to 30%, 30% to 40%, 30% to 50%, or 50% to 60%). In some embodiments, the physical characteristic is one or more of compression, expansion, tension, structure, size, porosity, surface chemistry, bending modulus, fracture or failure strain, resilience, permeability, swelling ratio, elasticity, electric conductivity, plasticity, resilience, resistance (e.g., creep resistance), strength (e.g., as measured by Young's modulus, tensile strength, compressive strength, impact strength, or yield strength), stress (e.g., compressive stress, shear stress, or tensile stress), load, and/or strain (e.g., as measured by deflection, deformation, strain at failure, or ultimate strain).
In any embodiment described herein, the change in a physical characteristic occurs in a portion of the dressing or across the entire dressing. In other embodiments, the change in a physical characteristic is non-uniform across the entire dressing or in a portion of the dressing. In yet other embodiments, the change in a physical characteristic is uniform across the entire dressing or in a portion of the dressing.
In any of the devices, dressings, apparatuses, and methods described herein, the one or more materials are configured in a random, non-geometric, and/or geometric arrangement to provide contraction and/or expansion in one or more directions in at least a portion of the area of the dressing. In particular embodiments, the arrangement is geometric (e.g., a uniform or non-uniform arrangement). In some embodiments, the geometric arrangement includes a first material arranged in a first direction and optionally a second material arranged in a second direction (e.g., where the second direction is approximately orthogonal to the first direction). In further embodiments, each of the first material or the second material is, independently, a shape-memory polymer, a shape-memory alloy, a thermal-responsive material, a pH-responsive material, a light-responsive material, a moisture-responsive material, a solvent-responsive or chemical exposure-responsive material, an electric field-responsive material, a magnetic field-responsive material, an actuator-embedded material, or an unstretched material (e.g., any described herein).
In any of the devices, dressings, apparatuses, and methods described herein, the one or more external stimuli is, independently, a change in temperature, pH, light, moisture, solvent, chemical exposure, electric field, and/or magnetic field (e.g., which can optionally result in mechanical, hydraulic, and/or pneumatic tuning).
In any embodiment described herein, exposure of the device (e.g., dressing or a layer of the device, as well as portions thereof) to two or more external stimuli (e.g., three, four, five, six, seven, eight, nine, ten, or more external stimuli) results in a change in two or more physical characteristics (e.g., three, four, five, six, seven, eight, nine, ten, or more changes in physical characteristics).
In any embodiment described herein, the regulatable layer or the unstretched layer includes two or more materials (e.g., three, four, five, six, seven, eight, nine, ten, or more materials). In particular embodiments, at least one of the materials (e.g., at least two, three, four, five, or more in one, two, three, four, or more layers) is a stimulus-responsive material (e.g., any described herein). Exemplary materials include a shape-memory polymer (e.g., including shape-memory polyurethane; block copolymers including poly(ethylene terephthalate), polystyrene, polyethylene glycol, poly(1,4-butadiene), polynorbornene, polyacrylate, and/or polyurethane, as well as shape-memory composites and shape-memory hybrids), a shape-memory alloy (e.g., any alloy described herein, such as a NiTi alloy), a thermal-responsive material (e.g., any such material described herein, such as polymers including poly-N-isopropylacrylam ide, poly-N-vinylcaprolactam, poly-N,N-diethylacrylamide, and/or a polyalkylacrylamide), a pH-responsive material (e.g., any described herein, such as polymers and copolymers including one or more polyacrylic acid, polymethacrylic acid, methacrylic acid/methyl methacrylate, and carboxylic derivatives of any monomer described herein), a light-responsive material (e.g., a polymer including one or more light-responsive switches, as described herein), a moisture-responsive material (e.g., a polymer including one or more ionic monomers, as described herein), a solvent-responsive or chemical exposure-responsive material (e.g., a polymer composite, as described herein), an electric field-responsive material (e.g., a polymer including one or more electric field-responsive switches, as described herein), a magnetic field-responsive material (e.g., a polymer including one or more magnetic field-responsive switches, as described herein), an actuator-embedded material (e.g., a material including one or more MEMS actuators, carbon nanotubes, piezoceramic actuators (e.g., optionally having one or more interdigitated electrodes), multilayered actuators, optical fibers, piezopolymeric films, piezoplates, piezofibers, shape-memory polymers, or shape-memory alloys). In other embodiments, at least one of the materials (e.g., at least two, three, four, five, or more in one, two, three, four, or more layers) is a conventional material and/or a rigid material (e.g., any described herein, such as alginate, benzyl hyaluronate, carboxymethylcellulose, cellulose acetate, chitosan, collagen, dextran, epoxy, gelatin, hyaluronic acid, hydrocolloids, nylon (e.g., nylon 6 or PA6), pectin, poly (3-hydroxyl butyrate-co-poly (3-hydroxyl valerate), polyacrylate (PA), polyacrylonitrile (PAN), polybenzimidazole (PBI), polycarbonate (PC), polycaprolactone (PCL), polyester (PE), polyethylene glycol (PEG), polyethylene oxide (PEO), PEO/polycarbonate/polyurethane (PEO/PC/PU), poly(ethylene-co-vinyl acetate) (PEVA), PEVA/polylactic acid (PEVA/PLA), poly (ethylene terephthalate) (PET), PET/poly (ethylene naphthalate) (PET/PEN) polyglactin, polyglycolic acid (PGA), polyglycolic acid/polylactic acid (PGA/PLA), polyimide (PI), polylactic acid (PLA), poly-L-lactide (PLLA), PLLA/PC/polyvinylcarbazole (PLLA/PC/PVCB), poly ((3-malic acid)-copolymers (PMLA), polymethacrylate (PMA), poly (methyl methacrylate) (PMMA), polystyrene (PS), polyurethane (PU), poly (vinyl alcohol) (PVA), polyvinylcarbazole (PVCB), polyvinyl chloride (PVC), polyvinylidenedifluoride (PVDF), polyvinylpyrrolidone (PVP), silicone, rayon, or combinations thereof).
In any embodiment described herein, the dressing is tunable without removal of a portion of the dressing (e.g., without removal of one or more layers of the dressing). In any embodiment described herein, the adhesive layer includes a continuous layer of one or more adhesive materials or a discontinuous layer of one or more adhesive materials. In further embodiments, the discontinuous layer includes one or more adhesive materials in a random, geometric, or non-geometric arrangement (e.g., an array of one or more adhesive materials). In particular embodiments, the adhesive layer is tunable (e.g., results in a change in a physical characteristic in the one or more adhesive materials in at least a portion of the dressing or across the entire dressing). Exemplary adhesive materials include any described herein, such as a biodegradable adhesive; a pressure sensitive adhesive (e.g., a natural rubber, synthetic rubber (e.g., a styrene-butadiene or styrene-ethylene copolymer), polyvinyl ether, polyurethane, acrylic, silicone, or a ethylene-vinyl acetate copolymer); a biocompatible matrix (e.g., collagen (e.g., a collagen sponge), low melting agarose (LMA), polylactic acid (PLA), and/or hyaluronic acid (e.g., hyaluranon)); a photosensitizer (e.g., Rose Bengal, riboflavin-5-phosphate (R-5-P), methylene blue (MB), N-hydroxypyridine-2-(1H)-thione (N-HTP), a porphyrin, or a chlorin, as well as precursors thereof); a photochemical agent (e.g., 1,8 naphthalimide); a synthetic glue (e.g., a cyanoacrylate adhesive, a polyethylene glycol adhesive, or a gelatin-resorcinol-formaldehyde adhesive); or a biologic sealant (e.g., a mixture of riboflavin-5-phosphate and fibrinogen, a fibrin-based sealant, an albumin-based sealant, or a starch-based sealant).
In any embodiment described herein, the devices, apparatuses, dressings, and/or methods include one or more therapeutic agents selected from growth factors, analgesics (e.g., an NSAID, a COX-2 inhibitor, an opioid, a glucocorticoid agent, a steroid, or a mineralocorticoid agent, or any described herein), antibiotics, antifungals, anti-inflammatory agents, antimicrobials (e.g., chlorhexidine-, iodine-, or silver-based agents, as described herein), antiseptics (e.g., an alcohol, a quaternary ammonium compound, or any described herein), antiproliferative agents, steroids (for example, steroids to prevent edema), agents which prevent post-inflammatory skin hyperpigmentation (e.g., hydroquinone, azelaic acid, kojic acid, mandelic acid, or niacinamide), emollients, hemostatic agents, procoagulative agents, anticoagulative agents, immune modulators, proteins, or vitamins. In particular embodiments, the therapeutic agent is a hemostatic agent, a procoagulative agent, an anticoagulative agent, or combinations thereof. In some embodiments, the therapeutic agent is selected from the group of anhydrous aluminum sulfate, anti-fibrinolytic agent(s) (e.g., epsilon aminocaproic acid, tranexamic acid, or the like), anti-platelet agent(s) (e.g., aspirin, dipyridamole, ticlopidine, clopidogrel, or prasugrel), calcium alginate, cellulose, chitosan, coagulation factor(s) (e.g., II, V, VII, VIII, IX, X, XI, XIII, or Von Willebrand factor, as well as activated forms thereof), collagen (e.g., microfibrillar collagen), coumarin derivative(s) or vitamin K antagonist(s) (e.g., warfarin (coumadin), acenocoumarol, atromentin, phenindione, or phenprocoumon), desmopressin, epinephrine, factor Xa inhibitor(s) (e.g., apixaban or rivaroxaban), fibrinogen, heparin or derivatives thereof (e.g., low molecular weight heparin, fondaparinux, or idraparinux), poly-N-acetyl glucosamine, potassium alum, propyl gallate, silver nitrate, thrombin, thrombin inhibitor(s) (e.g., argatroban, bivalirudin, dabigatran, hirudin, lepirudin, or ximelagatran), titanium oxide, or a zeolite (e.g., a calcium-loaded zeolite).
The tunable dressings of the invention may also include moisturizers, emollients, ointments (including occlusive ointments and non-occlusive ointments), lotions, or creams, which may, if desired, provide a liquid or vapor barrier. Ingredients typically found in these materials include petrolatum, lanolin, glycerin, panthenol, paraffin, microcrystalline wax, ceresine, wool fat, bees wax, emulsifying wax, ceremide, and vegetable oils (e.g., olive, peanut, or coconut oil).
The present invention features a kit including: (a) a tunable dressing (e.g., any described herein) and (b) an applicator, where the applicator is configured for positioning the dressing on a skin region. In some embodiments, the applicator includes a frame or any structure configured to affix a dressing to the skin region (e.g., a disposable frame or a disposable structure). In some embodiments, the applicator holds the dressing to allow for aligning, positioning, and/or placing the dressing on the desired skin region. In yet other embodiments, the applicator is configured to allow for affixing a tunable dressing immediately after or shortly after forming one or more incisions or excisions in the skin region (e.g., within about 30 seconds, as described herein). In other embodiments, the kit includes a mechanical ablation device.
The present invention also features a kit including: (a) a tunable dressing (e.g., any described herein) and (b) an apparatus for making incisions and/or excisions in a skin region (e.g., a microablation tool, such as a fractional laser microablation tool, a fractional radiofrequency microablation tool, or a fractional ultrasonic microablation tool). In some embodiments, the kit further includes an applicator (e.g., any described herein), where the applicator is structurally configured to attach to the apparatus for making one or more incisions and/or excisions and to release a device (e.g., a tunable dressing) after making such an incision or excision.
In further embodiments, any of the kits described herein can include one or more of instructions on how to use the device(s), an air blower, a skin cooling device (e.g., cold air blower, Zimmer cooler, cold plate or other cold surface applied to the skin, cold gas, or cold liquid), a heat gun, a heating pad, one or more therapeutic agents (e.g., any described herein, such as an anticoagulative and/or procoagulative agent, and optionally in combination with a useful dispenser for applying the therapeutic agent, such as a brush, spray, film, ointment, cream, lotion, or gel), one or more wound cleansers (e.g., including any antibiotic, antimicrobial, or antiseptic, such as those described herein, in any useful form, such as a brush, spray, film, ointment, cream, lotion, or gel), one or more debriding agents, and/or other suitable or useful materials.
The present invention features methods of skin tightening including: (i) affixing a device to a skin region, where the skin region includes a plurality of incised tissue portions and/or excised tissue portions (for example, where at least two of the tissue portions have an areal dimension that is less than about 1 mm2 and/or where at least two of the tissue portions has a dimension that is less than about 1 mm), and where the device provides contraction or expansion of the skin region in one or more directions; and (ii) adjusting the contraction or expansion by exposing the affixed device to one or more external stimuli that result in a change in a physical characteristic of the affixed device. In some embodiments, the areal dimension is less than or equal to about 1.0 mm2 (e.g., less than or equal to about 0.9 mm2, 0.8 mm2, 0.7 mm2, 0.6 mm2, 0.5 mm2, 0.4 mm2, 0.3 mm2, 0.2 mm2, 0.1 mm2, 0.07 mm2, 0.05 mm2, 0.03 mm2, 0.02 mm2, 0.01 mm2, 0.007 mm2, 0.005 mm2, 0.003 mm2, 0.002 mm2, or 0.001 mm2) or between about 0.001 mm2 and 1.0 mm2 (e.g., as described herein).
In some embodiments, the skin region or treated skin region includes a plurality of incised tissue portions and/or excised tissue portions (e.g., a plurality of holes and/or slits). In some embodiments, at least one (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, or more tissue portions, such as between about 2 and 100 tissue portions, as described herein) of the tissue portions has at least one dimension that is less than about 2.0 mm (e.g., less than or equal to about 1.5 mm, 1 mm, 0.75 mm, 0.5 mm, 0.3 mm, 0.2 mm, 0.1 mm, 0.075 mm, 0.05 mm, or 0.025 mm) or between about 0.025 mm and 2.0 mm (e.g., as described herein). In some embodiments, the plurality of incised tissue portions and/or excised tissue portions include one or more elliptical holes in the skin region. In other embodiments, the plurality of incised tissue portions and/or excised tissue portions includes any useful shape (e.g., a cylinder, hole, slit, elongated strip, or other geometries). In further embodiments, the areal fraction of the skin region to be removed is less than about 70% (e.g., less than about 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 10%, or 5%) or between about 5% and 80% (e.g., as described herein). In some embodiments, the plurality of tissue portions are incised or excised in any beneficial pattern within the skin region (e.g., as described herein).
In some embodiments, affixing step (i) is performed within about 30 seconds of incising and/or excising the skin region (e.g., within about 20, 15, 10, 5, 3 seconds or less after forming an incision or excision). In other embodiments, the adjusting step (ii) provides selectively closing or opening the incised tissue portions and/or excised tissue portions. In yet other embodiments, adjusting step (ii) includes adjusting the contraction or expansion across the entire device or a portion of the device. In further embodiments, the method results in controlling pleating in the skin region.
In any embodiment described herein, the devices, dressings, apparatuses, and methods are useful for treating one or more diseases, disorders, or conditions to improve skin appearance, to rejuvenate skin, and/or to tighten skin. Exemplary diseases, disorders, or conditions are described herein and include removal of pigment, tattoo removal, veins (e.g., spider veins or reticular veins), and/or vessels in the skin, as well as treatment of acne, allodynia, blemishes, ectopic dermatitis, hyperpigmentation, hyperplasia (e.g., lentigo or keratosis), loss of translucency, loss of elasticity, melasma (e.g., epidermal, dermal, or mixed subtypes), photodamage, rashes (e.g., erythematous, macular, papular, and/or bullous conditions), psoriasis, rhytides (or wrinkles, e.g., crow's feet, age-related rhytides, sun-related rhytides, or heredity-related rhytides), sallow color, scar contracture (e.g., relaxation of scar tissue), scarring (e.g., due to acne, surgery, or other trauma), skin aging, skin contraction (e.g., excessive tension in the skin), skin irritation/sensitivity, skin laxity (e.g., loose or sagging skin or other skin irregularities), striae (or stretch marks), vascular lesions (e.g., angioma, erythema, hemangioma, papule, port wine stain, rosacea, reticular vein, or telangiectasia), or any other unwanted skin irregularities.
By “about” is meant+/−10% of any recited value.
By “incised” tissue portion or “incision” is meant a cut, abrasion, or ablation of tissue, including a tissue portion in a skin region, or the act of cutting, abrading, destroying, or ablating tissue, a skin region, or one or more tissue portions. For example, an incision includes any cut, abrasion, or ablation into tissue, which can result in destruction of tissue or a portion thereof and, thereby, produce one or more holes or slits in the skin region. Exemplary methods of forming incised tissue portions or incisions include use of one or more blades, one or more solid needles, fractional laser ablation, fractional radiofrequency ablation, and/or fractional ultrasonic ablation, any useful tool for forming incisions, or any methods and apparatuses described herein.
By “excised” tissue portion or “excision” is meant a removed tissue, including a tissue portion from a skin region, or the act of removing tissue or one or more tissue portions from a skin region. For example, an excision includes any removed tissue or tissue portion from a skin region, which can result in excised tissue portions having a particular geometry (e.g., a cylindrical geometry) and produce one or more holes (i.e., negative space created by the removal of tissue) in the skin region. Exemplary methods of forming excised tissue portions or excisions include use of one or more hollow needles (optionally include one or more notches, extensions, protrusions, and/or barbs), one or more microaugers, one or more microabraders, any useful tool for forming excisions, or any methods and apparatuses described herein.
By “physical characteristic” is meant a physical property of a device (e.g., a dressing) or a material included in the device. Exemplary physical characteristics include compression (or compressive force), expansion, tension (e.g., as measured by tensile stress), structure, size, porosity, surface chemistry, bending modulus, fracture or failure strain, resilience, permeability, swelling ratio, elasticity (e.g., as measured by ultimate modulus of elasticity from the end-portion of stress-strain curves that is greater than 10 N/mm2), electric conductivity, plasticity, resilience, resistance (e.g., as measured by creep resistance), strength (e.g., as measured by Young's modulus (e.g., a Young's modulus that is greater than about 1×105 N/m), tensile strength (e.g., a tensile strength that is greater than about 2 N/mm2), compressive strength, impact strength, or yield strength), stress (e.g., as measured by compressive stress, shear stress, or tensile stress), load, strain (e.g., as measured by deflection, deformation, strain at failure, or ultimate strain (extension before rupture), e.g., greater than about 30% or from about 30% to 130%), and other parameters, as well as any described herein.
By “pleating” or “skin pleating” is meant any distortion in skin tissue (e.g., in the epidermal and/or dermal layers) that results in puckering and/or folding. An exemplary schematic of skin pleating is provided in
By “tunable” is meant capable of being adjusted, modified, or altered in one or more physical characteristics in response to one or more external stimuli. Any part of the device can be tunable. For instance, in a dressing, the regulatable layer and/or adhesive layer is tunable. In one non-limiting example, a tunable dressing is a dressing including at least one layer, where the structure of the layer changes in response to an external stimulus, such as a change in temperature. In another non-limiting example, a tunable dressing is a dressing including at least one material, where the structure of the material changes in response to an external stimulus. The change in one physical characteristic (e.g., change in structure at the molecular, microscopic, or macroscopic level) can exert a change in another physical characteristic (e.g., a change in compressive force or tension exerted by the dressing) in one or more directions (e.g., in the x-, y-, z-, xy-, xz-, yz-, and/or xyz-direction). In one non-limiting example, a polymeric material can be optimized to facilitate change in structure at the molecular level by altering the structure of the polymer chain (e.g., alterations to the side chain, linker regions, and/or precursor monomers), the particular block of the polymer (e.g., alterations to length, molecular weight, hydrophobicity, or hydrophilicity), or one or more co-polymeric blocks (e.g., alterations to weight percentage ratios or post-polymerization modifications). The extent of change can be either an increase or a decrease in a physical characteristic, as compared to before exposure of the stimulus. Such an increase or decrease can be of any useful extent, e.g., an increase or decrease of at least about 0.5% (e.g., at least about 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.5%, 1.7%, 2.0%, 2.2%, 2.5%, 2.7%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, 10.5%, 15%, 20%, 3.5%, 0.5% to 3%, 0.5% to 2.7%, 0.5% to 2.5%, 0.5% to 2.2%, 0.5% to 2.0%, 0.5% to 1.7, 0.5% to 1.5%, 0.5% to 1.2, 0.5% to 1.1%, 0.5% to 1.0%, 0.5% to 0.9%, 0.5% to 0.8%, 0.5% to 0.7%, 0.5% to 0.6%, 0.7% to 20%, 0.7% to 15%, 0.7% to 10.5%, 0.7% to 10%, 0.7% to 9.5%, 0.7% to 9%, 0.7% to 8.5%, 0.7% to 8%, 0.7% to 7.5%, 0.7% to 7%, 0.7% to 6.5%, 0.7% to 6%, 0.7% to 5.5%, 0.7% to 5%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, or more) or from about 0.5% to 20% (e.g., from about 0.5% to 15%, 0.5% to 10.5%, 0.5% to 10%, 0.5% to 9.5%, 0.5% to 9%, 0.5% to 8.5%, 0.5% to 8%, 0.5% to 7.5%, 0.5% to 7%, 0.5% to 6.5%, 0.5% to 6%, 0.5% to 5.5%, 0.5% to 5%, 0.5% to 4.5%, 0.5% to 4%, 0.5% to 0.7% to 4.5%, 0.7% to 4%, 0.7% to 3.5%, 0.7% to 3%, 0.7% to 2.7%, 0.7% to 2.5%, 0.7% to 2.2%, 0.7% to 2.0%, 0.7% to 1.7%, 0.7% to 1.5%, 0.7% to 1.2%, 0.7% to 1.1%, 0.7% to 1.0%, 07% to 0.9%, 0.7% to 0.8%, 1.0% to 20%, 1.0% to 15%, 1.0% to 10.5%, 1.0% to 10%, 1.0% to 9.5%, 1.0% to 9%, 1.0% to 8.5%, 1.0% to 8%, 1.0% to 7.5%, 1.0% to 7%, 1.0% to 6.5%, 1.0% to 6%, 1.0% to 5.5%, 1.0% to 5%, 1.0% to 4.5%, 1.0% to 4%, 1.0% to 3.5%, 1.0% to 3%, 1.0% to 2.7%, 1.0% to 2.5%, 1.0% to 2.2%, 1.0% to 2.0%, 1.0% to 1.7%, 1.0% to 1.5%, 1.0% to 1.2%, 1.0% to 1.1%, 1.5% to 20%, 1.5% to 15%, 1.5% to 10.5%, 1.5% to 10%, 1.5% to 9.5%, 1.5% to 9%, 1.5% to 8.5%, 1.5% to 8%, 1.5% to 7.5%, 1.5% to 7%, 1.5% to 6.5%, 1.5% to 6%, 1.5% to 5.5%, 1.5% to 5%, 1.5% to 4.5%, 1.5% to 4%, 1.5% to 3.5%, 1.5% to 3%, 1.5% to 2.7%, 1.5% to 2.5%, 1.5% to 2.2%, 1.5% to 2.0%, 1.5% to 1.7%, 2.0% to 20%, 2.0% to 15%, 2.0% to 10.5%, 2.0% to 10%, 2.0% to 9.5%, 2.0% to 9%, 2.0% to 8.5%, 2.0% to 8%, 2.0% to 7.5%, 2.0% to 7%, 2.0% to 6.5%, 2.0% to 6%, 2.0% to 5.5%, 2.0% to 5%, 2.0% to 4.5%, 2.0% to 4%, 2.0% to 3.5%, 2.0% to 3%, 2.0% to 2.7%, 2.0% to 2.5%, 2.0% to 2.2%, 2.5% to 20%, 2.5% to 15%, 2.5% to 10.5%, 2.5% to 10%, 2.5% to 9.5%, 2.5% to 9%, 2.5% to 8.5%, 2.5% to 8%, 2.5% to 7.5%, 2.5% to 7%, 2.5% to 6.5%, 2.5% to 6%, 2.5% to 5.5%, 2.5% to 5%, 2.5% to 4.5%, 2.5% to 4%, 2.5% to 3.5%, 2.5% to 3%, 2.5% to 2.7%, 3.0% to 20%, 3.0% to 15%, 3.0% to 10.5%, 3.0% to 10%, 3.0% to 9.5%, 3.0% to 9%, 3.0% to 8.5%, 3.0% to 8%, 3.0% to 7.5%, 3.0% to 7%, 3.0% to 6.5%, 3.0% to 6%, 3.0% to 5.5%, 3.0% to 5%, 3.0% to 4.5%, 3.0% to 4%, 3.0% to 3.5%, 4.0% to 20%, 4.0% to 15%, 3.5% to 10.5%, 4.0% to 10%, 4.0% to 9.5%, 4.0% to 9%, 4.0% to 8.5%, 4.0% to 8%, 4.0% to 7.5%, 4.0% to 7%, 4.0% to 6.5%, 4.0% to 6%, 4.0% to 5.5%, 4.0% to 5%, 4.0% to 4.5%, 5.0% to 20%, 5.0% to 15%, 5.0% to 10.5%, 5.0% to 10%, 5.0% to 9.5%, 5.0% to 9%, 5.0% to 8.5%, 5.0% to 8%, 5.0% to 7.5%, 5.0% to 7%, 5.0% to 6.5%, 5.0% to 6%, or 5.0% to 5.5%), 20% to 30%, 30% to 40%, 30% to 50%, or 50% to 60% as compared to before exposure of a stimulus. For a particular device (e.g., a dressing), further tunability can be accomplished by any processing or post-processing known in the art (e.g., by using one or more hydrophilic or hydrophobic coatings, hydrogels, foams, colloids, etc.), thereby providing further control of one or more physical characteristics.
By “subject” is meant a human or non-human animal (e.g., a mammal).
By “treating” a disease, disorder, or condition in a subject is meant reducing at least one symptom of the disease, disorder, or condition by affixing a device (e.g., a dressing) to the subject.
By “prophylactically treating” a disease, disorder, or condition in a subject is meant reducing the frequency of occurrence or severity of (e.g., preventing) a disease, disorder or condition by affixing a device (e.g., a dressing) to the subject prior to the appearance of a symptom of the disease, disorder, or condition.
Other features and advantages of the invention will be apparent from the following Detailed Description and the claims.
This invention relates to methods and devices for the tightening of skin and/or reduction of skin laxity by selectively opening or closing a plurality of small wounds formed by incision or excision of tissue.
For example, tissue excision can be performed by fractional ablation of the epidermal and/or dermal layer of the skin with a hollow coring needle, by fractional laser ablation, by fractional radiofrequency ablation, and/or by fractional ultrasonic ablation. Various methods and devices are proposed to close the small wounds, including tunable or smart dressings that allow for titration of the tightening effect after application to the skin of a patient.
In particular embodiments, the present invention provides one or more of the following advantages. First, the methods and devices herein enable visualization of results in real time during the course of the treatment. One can envision asking the patient for feedback in real time during the treatment and adjusting the tightening to the patient preference. Second, the methods and devices herein are tunable, thereby allowing for titration of tightening after surgical hole or slit formation. For example, the tunable or smart dressings described herein allow adjustment of the tightening intensity, direction, and spatial distribution after the dressing has been applied or affixed to the patient's skin. In another example, titratable tightening can be achieved by selectively closing or opening a subset of slits or holes produced in an array. Third, the methods and devices herein requires less skill than that of a surgeon. One can envision treatment of patients in an outpatient setting, rather than requiring an inpatient, surgical setting. Fourth, the methods and devices herein constitute minimally invasive techniques, which can provide more predictable results and/or risk factors than that for more invasive techniques (e.g., plastic surgery) or non-invasive energy-based techniques (e.g., laser, radiofrequency, or ultrasound). Fifth, the methods and devices herein can allow for less discriminate methods for treating the skin by forming holes or slits because the methods and devices allow for more discriminate control for closing such holes or slits. Sixth, the methods and devices herein can allow for rapid closing of holes or slits after treating the skin (e.g., within a few seconds after treating skin, such as within ten seconds), thereby minimizing the extent of bleeding and/or clotting within the holes or slits. Finally, the methods and devices herein can be useful for maximizing the tightening effect while minimizing healing time by optimizing tightening (e.g., by controlling the extent of skin pleating, such as by increasing the extent of skin pleating for some applications or skin regions and by decreasing the extent of skin pleating for other applications or skin regions, as described herein).
Devices for Closure of Holes
The present invention features methods and devices to tighten skin having one or more incised or excised tissue portions. In particular, exemplary devices include selectively opening or closing of holes and/or slits using a tunable dressing.
Tunable Dressings
The present invention features a tunable dressing having a regulatable layer formed from any useful material(s) (e.g., any described herein, such as a shape-memory polymer). In particular, exposure of the regulatable layer to one or more external stimuli results in a change in a physical characteristic in the material(s). This change can extend across the entire dressing (e.g., across the entire x-, y-, and/or z-direction of the dressing, including planar and non-planar changes) or in a portion or part of the dressing (e.g., at a localized area of the dressing, which has been locally exposed to a stimulus and thereby results in a change in one or more physical characteristics in the x-, y-, and/or z-direction).
Further, the dressing can provide a variable tightening effect across the entire dressing (e.g., varying degrees of tightening across the entire x-, y-, and/or z-direction of the dressing, including planar and non-planar changes) or in a portion or part of the dressing (e.g., varying degrees of tightening at a localized area of the dressing).
Any useful physical characteristic of the device (e.g., dressing) or material in the device can be changed. Exemplary physical characteristics include compression (or compressive force, e.g., lateral compression), expansion (e.g., lateral expansion), tension (e.g., as measured by tensile stress), structure, size, porosity, surface chemistry, bending modulus, fracture or failure strain, resilience, permeability, swelling ratio, elasticity (e.g., as measured by ultimate modulus of elasticity from the end-portion of stress-strain curves that is greater than 10 N/mm2 (e.g., greater than about 15 N/mm2, 20 N/mm2, 25 N/mm2, 30 N/mm2, 35 N/mm2, or 40 N/mm2) or between about 10 N/mm2 and 200 N/mm2 (e.g., about 10 N/mm2 and 150 N/mm2, 10 N/mm2 and 100 N/mm2, 15 N/mm2 and 200 N/mm2, 15 N/mm2 and 150 N/mm2, 15 N/mm2 and 100 N/mm2, 20 N/mm2 and 200 N/mm2, 20 N/mm2 and 150 N/mm2, or 20 N/mm2 and 100 N/mm2)), electric conductivity, plasticity, resilience, resistance (e.g., as measured by creep resistance), strength (e.g., as measured by Young's modulus, such as a Young's modulus that is greater than about 1×105 NM−2 (e.g., greater than about 2.0×105 N/m2, 2.5×105 N/m2, 3.5×105 N/m2, 4×105 N/m2, 4.5×105 N/m2, 5×105 N/m2, 6×105 N/m2, 7×105 N/m2, 8×105 N/m2, 6×105 N/m2, or 10×105 N/m2), tensile strength, such as a tensile strength that is greater than about 2 N/mm2 (e.g., greater than about 5 N/mm2, 7 N/mm2, 10 N/mm2, 15 N/mm2, 17 N/mm2, 20 N/mm2, 25 N/mm2, 27 N/mm2, 30 N/mm2, or 35 N/mm2) or between about 5 N/mm2 and 40 N/mm2 (e.g., between about 15 N/mm2 and 30 N/mm2, 15 N/mm2 and 35 N/mm2, 10 N/mm2 and 30 N/mm2, or 10 N/mm2 and 35 N/mm2), compressive strength, impact strength, or yield strength), stress (e.g., as measured by compressive stress, shear stress, or tensile stress), load (e.g., load per millimeter width of at least 0.1 Newtons at a strain of at least 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or higher), strain (e.g., as measured by deflection, deformation, strain at failure, or ultimate strain (extension before rupture), e.g., greater than about 30% (e.g., greater than about 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, 100%, 110%, 115%, or 120%) or from about 30% to 130% (e.g., about 30% to 120%, 30% to 115%, 30% to 110%, 30% to 100%, 30% to 95%, 30% to 90%, 30% to 85%, 30% to 80%, 30% to 75%, 30% to 70%, 30% to 65%, 30% to 60%, 30% to 55%, 30% to 50%, 35% to 130%, 35% to 120%, 35% to 115%, 35% to 110%, 35% to 100%, 35% to 95%, 35% to 90%, 35% to 85%, 35% to 80%, 35% to 75%, 35% to 70%, 35% to 65%, 35% to 60%, 35% to 55%, 35% to 50%, 40% to 130%, 40% to 120%, 40% to 115%, 40% to 110%, 40% to 100%, 40% to 95%, 40% to 90%, 40% to 85%, 40% to 80%, 40% to 75%, 40% to 70%, 40% to 65%, 40% to 60%, 40% to 55%, 40% to 50%, 50% to 130%, 50% to 130%, 50% to 120%, 50% to 115%, 50% to 110%, 50% to 100%, 50% to 95%, 50% to 90%, 50% to 85%, 50% to 80%, 50% to 75%, 50% to 70%, 50% to 65%, 50% to 60%, 50% to 55%, 60% to 130%, 60% to 120%, 60% to 115%, 60% to 110%, 60% to 100%, 60% to 95%, 60% to 90%, 60% to 85%, 60% to 80%, 60% to 75%, 60% to 70%, 60% to 65%, 70% to 130%, 70% to 120%, 70% to 115%, 70% to 110%, 70% to 100%, 70% to 95%, 70% to 90%, 70% to 85%, 70% to 80%, 70% to 75%, 75% to 130%, 75% to 120%, 75% to 115%, 75% to 110%, 75% to 100%, 75% to 95%, 75% to 90%, 75% to 85%, 75% to 80%, 80% to 120%, 80% to 115%, 80% to 110%, 80% to 100%, 80% to 95%, 80% to 90%, or 80% to 85%)), and other parameters.
Further, the extent or intensity of the physical characteristic can be increased or decreased after exposure to one or more stimuli. Exemplary physical characteristics include an increase in tension, a decrease in tension (e.g., of the dressing), an increase in compressive force (e.g., lateral compressive force that is exerted by the dressing), a decrease in compressive force (e.g., lateral compressive force that is exerted by the dressing), compression in one or more directions of the dressing, and/or expansion in one or more directions of the dressing.
The change in one or more physical characteristics can be optimized based on the desired response to a stimulus, location of the skin region to be treated, or any other useful parameter. For instance, the change in physical characteristic can be optimized for placement in the eye region, where the eye region includes Langer lines having particular directions, and the directionality of compression or expansion exerted by the dressing can be perpendicular to such Langer lines to promote skin tightening. Further, optimization that takes into account Langer lines can be utilized on any area of the body. Langer lines correspond to the orientation of native collagen fibers in the dermis. The closing of ablations (including micro-ablations) following Langer line orientation maximizes wound closure efficiency and tightening, and may be applied to any area of the body.
The directionality of the change in the physical characteristics, relative to the device (e.g., dressing) or skin region, can also be optimized. In particular embodiments, the direction of skin tightening is determined by the directionality of the physical characteristic change. For instance, the direction of the tensile force or compressive force can be in the x-, y-, and/or z-direction with respect to the device or skin region (see, e.g.,
The intensity of the change in the physical characteristic(s), as compared to before exposure to one or more stimuli, can also be optimized. Such optimization can include selection of particular materials (e.g., one or more particular shape-memory polymers or alloys) or combinations of such materials to produce the intended effect (e.g., a combination of a rigid polymer with one or more particular shape-memory polymers or alloys), as well as arrangement (e.g., geometric or random arrangement) of such material(s) within a single layer in a device (e.g., within a single regulatable layer) or in separate multiple layers (e.g., in more than one regulatable layers, such as one, two, three, or more layers) in a device to produce the intended directionality and/or intensity of the physical characteristic(s).
The external stimulus to activate or induce the physical characteristic can be any useful stimulus. Exemplary stimulus includes a change in temperature, pH, light, moisture, solvent or chemical exposure, electric field, and/or magnetic field. In particular embodiments, the device includes one or more materials (e.g., in one or more layers) that can be activated by different external stimuli. An exemplary device is provided in
Furthermore, the change in physical characteristic or exposure of a stimulus can include the entire device or only a portion of the device. For example, the entire dressing can be exposed to an external stimulus to induce a change in compression over the entire skin region to which the dressing is affixed. Although the change in compression can occur over the entire skin region, the extent or intensity of compression can vary along the x-, y-, and/or z-axes or within the xy-, xz-, yz-, and/or xyz-planes of the skin region. In another example, the dressing can be locally exposed to an external stimulus to induce a change in compression over a portion of the device (i.e., thereby resulting in a change in compression over a portion of the skin region). In particular embodiments, the device (e.g., a dressing having a regulatable layer and/or an unstretched layer) contracts or expands in one or more directions (e.g., in planar and non-planar directions) in a portion of the area of the device after exposure to a stimulus. Such a device may be used for any method described herein, such as to reduce pleating.
Tunability of the dressing can provide numerous benefits. For instance, such tunability can allow for real-time control of compressing and/or expanding the dressing after affixation. This level of control can allow for personalized treatment of the patient based on the disease, disorder, or condition to be treated; the optimal cosmetic effect to be achieved; the optimal closure process to be achieved; and/or the timing and extent of the healing process observed for the particular patient. Furthermore, tunability can allow for less discriminate control over how the incisions or excisions in the skin region are made, as well as more discriminate control over selectively closing or opening the incisions or excisions.
The tunable dressing can be affixed to the entire treated skin region or in a portion of the treated skin region. Directional or non-directional tightening can be achieved by producing a geometric arrangement of incisions and/or excisions that are treated similarly. Alternatively, such tightening can be achieved by a non-geometric arrangement of incisions and/or excisions in which only some of the incisions and/or excisions are opened or closed using a tunable dressing.
The tunable dressing can include an adhesive layer (e.g., formed from any adhesive material described herein). The adhesive layer can be continuous (i.e., a continuous layer of one or more adhesive materials attached to the proximal surface of a dressing) or discontinuous (i.e., a non-continuous layer of one or more adhesive materials attached to the proximal surface of a dressing). The adhesive layer can include any useful arrangement of the adhesive material. For instance, the adhesive layer can be tunable and allows for controlled compression or expansion. In some embodiments, an adhesive layer includes a random, non-geometric, or geometric array of an adhesive material for tunability. In particular embodiments, the array allows for directional or non-directional compression and/or expansion as the dressing compresses and/or expands. In particular embodiments, the adhesive layer is discontinuous and includes an array of an adhesive material (e.g., an array of dots, where each dot gets closer together as the dressing compresses and each dot gets further apart as the dressing expands). Exemplary adhesive materials are described herein and include materials that promote collagen cross-linking, such as riboflavin or Rose Bengal, synthetic glues (e.g., cyanoacrylate, polyethylene glycol, or gelatin-resorcinol-formaldehyde), or biologic sealants (e.g., albumin-based or fibrin-based sealants that promote clotting).
The material(s) of the device can include any useful arrangement or form. Exemplary arrangements include a geometric arrangement of one or more materials within a single layer (e.g., a linear array or a grid of one or more materials in a single regulatable layer; or a linear array or a grid of one or more adhesive materials in a single adhesive layer); a geometric arrangement of one or more materials within multiple layers (e.g., in a multilayer dressing having more than one layer, where each layer includes a linear array or a grid of one or more materials and each linear array or grid is optimized for directional compression or expansion); a random, non-uniform arrangement of one or more materials in a single layer or across a plurality of layers; or combinations thereof. In some embodiments, a layer includes a first array of a first material and a second array of a second material, where each array has a geometric arrangement that promotes directional or non-directional compression or expansion. In particular embodiments, the first array is orthogonal to the second array. The materials can also be in any useful form, e.g., a film, a membrane (e.g., as in temperature shrink wrap), or an actuator having more complex geometries. In other embodiments, an adhesive layer includes an array of an adhesive material, where the array has a random, non-geometric, or geometric arrangement that allows for directional or non-directional compression or expansion as the regulatable layer or dressing compresses and/or expands. In particular embodiments, the adhesive layer is discontinuous and includes an array of an adhesive material (e.g., an array of dots of an adhesive material).
The material(s) of the device can optionally include one or more actuators in any useful arrangement or form. Such actuators can be embedded in one or more materials and in one or more layers (e.g., in the regulatable layer and/or the adhesive layer). Furthermore, the actuators can allow for uniform, non-uniform, or variable control (e.g., compression and/or expansion) across the entire device or in a portion of the device. Thus, actuators can be embedded across the entire device, in a portion of the device, in one layer, or in multiple layers. In particular embodiments, the stimulus-responsive material includes one or more actuators that respond to one or more stimuli, where the material includes a plurality of one type of actuator or a plurality of different actuators. The actuators in each layer can be arranged in any useful random, non-geometric, or geometric arrangement. Alternatively, the actuators can be arranged within multiple layers (e.g., in a multilayer dressing having more than one layer, where each layer includes a linear array or a grid of one or more actuators and each linear array or grid is optimized for directional compression or expansion); a random, non-uniform arrangement of one or more actuators in a single layer or across a plurality of layers; or combinations thereof. Exemplary materials including one or more actuators are described herein.
The material(s) or layer(s) in a device (e.g., a dressing) can include an unstretched layer (e.g., including any material described herein) and an adhesive layer. The unstretched layer can include one or more unstretched materials, including those having sufficient rigidity to hinder stretching and those having one or more stretchable polymers that are not stretched prior to affixing to a skin region. The material(s) or layer(s) in a device (e.g., a dressing) can include an adhesive layer, a regulatable layer, as well as one or more additional, optional layers or fasteners (e.g., staples, sutures, etc.). Exemplary optional layers include an occlusion layer (e.g., to control humidity and/or promote wound healing), an absorption layer (e.g., to absorb wound exudate), a reinforcement layer (e.g., to reinforce the layer and optionally formed from low-density polyethylene (LDPE), fluorinated ethylene propylene (FEP), or nylon), and/or a delivery layer (e.g., to delivery one or more therapeutic agents, as described herein).
The device (e.g., dressing) can optionally include an applicator, as described herein. In some embodiments, the applicator is a frame or any other useful structure that provides sufficient support to the tunable dressing and/or provides a sterile method to affix the tunable dressing to the treated skin region. In other embodiments, the applicator is configured to attach to an apparatus that forms one or more incisions and/or excisions, where the applicator allows for releasing and/or affixing the tunable dressing after the formation of such an incision or excision (e.g., within about 30, 25, 20, 15, 10, 5, 3 seconds or less after forming an incision or excision).
The device can be of any cosmetically appealing color, shape, and/or material. For example, the tunable dressing can be provided in a skin tone color or is transparent or semi-transparent. Such transparent or semi-transparent dressings can additionally be helpful for visualization, e.g., for real-time tunability of the dressing and/or for affixing the dressing to the treated skin region.
Exemplary tunable dressings and materials for constructing such dressing are described herein.
Testing of Devices
To optimized function of any of the devices described herein, the appropriate force (e.g., compressive, tensile, and/or lateral force) and/or geometric arrangement of the device (e.g., a dressing) can be tested by any useful metric. Exemplary metrics include any useful endpoint, such as presence or absence of melanocytes, melanin in keratinocytes, collagen production, elastin, scarring and/or infection, fibroblast activity, inflammation, macrophage and/or leukocyte recruitment, or the relative thickness of the papillary dermis and/or epidermis; melanin index, which is a unitless variable that quantifies the concentration of melanin in skin (e.g., by obtaining a reflectance spectrum and determining the slope of the log of the inverse reflectance values for wavelengths between 620 and 700 nm); erythema index, which is a unitless variable that quantifies the concentration of melanin and/or hemoglobin in skin (e.g., by obtaining an absorption spectrum and determining the log of the ratio of the reflectance at 635 nm and at 565 nm, such as by using a commercially available reflectance instrument from Diastron (Hampshire, U.K.)); transepidermal water loss, which measures the quantity of water that passes from the inside of a body through the epidermal layer; the Glogau wrinkle assessment scale with a scoring system of type I (no wrinkles), type II (wrinkles in motion), type III (wrinkles at rest), and type IV (only wrinkles), as described in Glogau, “Aesthetic and anatomic analysis of the aging skin,” Semin. Cutan. Med. Surg. 15(3):134-138 (1996); and/or the Fitzpatrick wrinkle assessment scale (FWAS) or modified FWAS (MWAS) with a scoring system of 0 (no wrinkle: no visible wrinkle, continuous skin line), 0.5 (very shallow yet visible wrinkle), 1 (fine wrinkle: visible wrinkle and slight indentation), 1.5 (visible wrinkle and clear indentation with less than 1 mm wrinkle depth), 2 (moderate wrinkle: clearly visible wrinkle with 1 mm to 2 mm wrinkle depth), 2.5 (prominent visible wrinkle with more than 2 mm and up to 3 mm wrinkle depth), and 3 (deep wrinkle: deep and furrow wrinkle with more than 3 mm wrinkle depth).
Further Processing of Devices
The devices (e.g., dressings) can be further processed prior to affixing to the subject. Exemplary processes include sterilization (e.g., with ultrasound, ultraviolet light, heat, and/or plasma); treatment with one or more antimicrobials (e.g., treatment with chlorhexidine gluconate or silver, such as a silver nitrate or Ag+ in one or more useful carriers, as described herein); and/or treatment with one or more agents, e.g., to form a coating on the dressing, where exemplary agents include a biocompatible matrix (e.g., those including at least one of collagen (e.g., a collagen sponge), low melting agarose (LMA), polylactic acid (PLA), and/or hyaluronic acid (e.g., hyaluranon)), a photosensitizer (e.g., Rose Bengal, riboflavin-5-phosphate (R—S—P), methylene blue (MB), N-hydroxypyridine-2-(1H)-thione (N-HTP), a porphyrin, or a chlorin, as well as precursors thereof), a photochemical agent (e.g., 1,8 naphthalimide), a fibrin sealant, a cyanoacrylate adhesive, or a tissue glue composed of a mixture of riboflavin-5-phosphate and fibrinogen
Methods of Skin Tightening
The present invention relates to various methods and devices (e.g., dressings) used to selectively open or close incisions and/or excisions (e.g., all or a portion of such incisions, such as microslits, and/or excisions, such as holes) formed in the skin region by the incised or excised tissue portions. The devices can be affixed to the entire treated skin region or in a portion of the treated skin region, which allow for directional or non-directional tightening by producing a geometric or non-geometric arrangement of incisions and/or excisions that are treated similarly or differently. Further, the devices can provide uniform or non-uniform compression and/or expression across the entire device or a portion thereof. Accordingly, these methods and devices can result in reducing the skin surface and/or tightening of the skin.
The methods can include contraction or expansion in one or more directions in at least a portion of the device (e.g., the dressing). The methods include, for example, affixing a device to a skin region having a plurality of incised tissue portions and/or excised tissue portions (e.g., where at least two of said tissue portions has at least one dimension that is less than about 1 mm or an areal dimension that is less than about 1 mm2). The device provides contraction or expansion of the skin region in one or more directions (e.g., in the x-, y-, z-, xy-, xz-, yz-, and/or xyz-directions, as described herein), where such contraction or expansion can be uniform or non-uniform. Furthermore, contraction or expansion arises by exposing an affixed device to one or more external stimuli (e.g., any described herein) that results in a change in a physical characteristic of the device. In addition, such contraction and/or expansion can be adjusted after affixing the device. For example, after treating the skin and affixing the device, the device can result in expansion of the skin region and then later exposed to an external stimulus to further expand or to compress the skin region. In this manner, the device is tunable.
The present invention also includes methods of tightening skin in a preferred direction. An exemplary method is provided in
The present invention also includes optimizing the dimension of the incised or excised tissue portions to promote wound healing. Exemplary dimensions include circular and non-circular holes, such as elliptical holes (e.g., as viewed from the xy-plane). Non-circular holes can be formed by using an apparatus having a non-circular cross-section (e.g., a blade or a tube, such as a hollow tube, having a non-circular cross-section) or by pre-stretching the skin before treatment with an apparatus having a circular cross-section (e.g., a circular coring needle generates an elliptical hole in a non-stretched skin). In some embodiments, the long axis of the ellipse is perpendicular to the pre-stretching direction, where the elliptical hole can generate skin tightening preferentially in the direction of the short axis of the ellipse. Accordingly, the devices of the invention (e.g., a dressing, as described herein) can be affixed to a skin portion including one or more elliptical holes or one or more incised or excised tissue portions having one or more elliptical geometries.
The methods and devices herein can allow for less discriminate methods for treating the skin by forming holes or slits because the methods and devices allow for more discriminate control for closing or opening such holes or slits. For instance, tunable dressings allow for real-time control for compressing or expanding holes or slits. Exemplary modes of control include the extent of compression or expansion, the directionality of compression or expansion (e.g., in the x-, y-, z-, xy-, yz-, xz-, or xyz-direction), and/or timing of applying the compression or expansion (e.g., within a few seconds, such as within 30, 20, 15, 10, 5, 3 seconds, or less).
Control of Skin Pleating
Furthermore, the methods and devices of the invention can be used to control skin pleating. For example, when using dressing to compress the skin and close holes and/or slits, it may be advantageous to apply an optimal compression level that can be adjusted during the treatment period and after affixing the dressing. During the setting of the tissue, skin pleating can be beneficial in some instances and should be avoided in other instances. After the excision or incision, the tissue can be compressed or expanded in order to set the tissue. In particular examples, the setting time may be as short as 2-4 days, and the tunable dressing provides compression or expansion prior to this setting time. Accordingly, the methods and devices or the invention can be used to control the level of compression and/or expansion exerted by the device to increase and/or decrease the extent of skin pleating.
The state of the tissue can provide feedback about the optimal compression level, such that tissue pleating can be controlled. Tissue pleating may affect the wound healing process, where
The methods and devices for skin tightening can also be optimized for conforming to uneven skin surfaces, whether such surfaces arise from a particular disease or condition (e.g., any described herein) or from the anatomical location of the skin region (e.g., in the brow, chin, or breast regions). Such unevenness can occur in any direction or plane, including non-planar and planar unevenness. In some embodiments, the tunable dressing includes one or more materials that allow for contraction or expansion of the skin region in one or more directions (e.g., in the x-, y-, z-, xy-, xz-, yz-, and/or xyz-directions, as described herein), as well as in planar and non-planar directions (e.g., in the xy-, xz-, yz-, and/or xyz-planes). When treating uneven skin surfaces, tissue pleating can be a particular concern that should be controlled. Thus, the methods, devices, and tunable dressing described herein can be useful for optimizing compression and/or expansion levels in any useful direction(s) for treating uneven skin surfaces, while controlling pleating.
Materials
The methods, devices, and apparatuses of the invention can include any useful materials. In a tunable dressing, the regulatable layer can include one or more stimulus-responsive materials (e.g., a shape-memory material, a shape-memory polymer, a shape-memory alloy, a thermal-responsive material, a pH-responsive material, a light-responsive material, a moisture-responsive material, a solvent-responsive or chemical exposure-responsive material, an electric field-responsive material, a magnetic field-responsive material, an actuator-embedded material, and/or an unstretched material). The adhesive layer can include one or more adhesive materials (e.g., pressure sensitive adhesives).
The materials can include arise from any useful mechanism for compressing and/or expanding the device, as well as any useful stimulus. Such mechanisms include mechanical, hydraulic, and/or pneumatic modes of operation. Exemplary stimulus includes a change in temperature, pH, light, moisture, solvent, chemical exposure, electric field, and/or magnetic field, which can optionally result in mechanical, hydraulic, and/or pneumatic tuning.
The materials can be of any useful form. Exemplary forms include an emulsion, a fiber, a film, a foam, a hydrogel, a solution, a laminate, or any other form that can be further processed, such as shaped, cast, extruded, molded (e.g., by blow molding, injection molding, or resin transfer molding), woven, cross-linked, deposited, laminated, and/or spun (e.g., by wet spinning, electrospinning, and/or melt spinning) to any useful article (e.g., a dressing or one or more layers within a dressing).
Shape-Memory Materials
Shape-memory materials (SMMs) can change their physical conformation (or shape) under an external stimulus (e.g., a thermal stimulus). For example, an article formed from an SMM or coated with an SMM can possess a first, desired shape and a second, temporary shape. When the SMM is regulatable by temperature, switching between these two shapes is achieved by heating or cooling above the glass or melting transition temperature of the SMM. SMMs may have a completely reversible transition (e.g., in a material that returns to its original shape) or a partially reversible transition with hysteresis (e.g., resulting in a material requiring additional energy to return to its original shape). SMMs can have multiple external stimulus responses, such as responses to both temperature and light or temperature and magnetic fields.
SMIVIs include both shape-memory polymers (SMPs) and shape-memory alloys (SMAs). SMPs can be in any useful form, such as in the form of the parent polymer chain, gels, hydrogels, emulsions, or micelles. Exemplary SMPs include shape-memory polyurethane (e.g., a poly(propylene glycol) (PPG), 4,4′-diphenylmethane diisocyanate (MDI), and dimethylolpropionic acid (DMPA) (PPG/MDI/DMPA) copolymer, where —NCO is optionally end-capped with methyl ethyl ketoxime (MEKO), or polymers including dimethyloldihydroxyethylene urea (DMDHEU) and/or 1,2,3,4-butane tetra-carboxylic acid (BTCA)); a poly(ethylene terephthalate)/poly(caprolactone) (PET/PCL) block copolymer (e.g., optionally crosslinked with maleic anhydride, glycerin, or dim ethyl 5-isophthalate); a polyethylene terephthalate/polyethylene oxide (PET/PEO) block copolymer; an ABA triblock copolymer made from poly(2-methyl-2-oxazoline) and polytetrahydrofuran; a polystyrene and poly(1,4-butadiene) (PS/PBD) block copolymer; a polyethylene glycol/4,4′-diphenylmethane diisocyanate/pentaerythritol (PEG/MDI/PE) copolymer; polynorbornene ((C7H10)x or Norsorex®, available from Astrotech Advanced Elastomer Products GmbH, Vienna, Austria); organic-inorganic hybrid polymers including polynorbornene units partially substituted by polyhedral oligosilsesquioxane (FOSS); an acrylate-based polymer; a styrene-based polymer; an epoxy-based polymer); and shape-memory fibers (e.g., oligomers prepared with polyol as the soft segment and small size diols and MDI as the hard segment).
Exemplary SMAs include a nickel-titanium (NiTi) alloy (e.g., Nitinol™, available from Nitinol Devices & Components, Inc., Fremont, CA, of approximately 55% Ni); a nickel-titanium-niobium (NiTiNb) alloy; a nickel-iron-gallium (NiFeGa) alloy; a nickel-manganese-gallium (NiMnGa) alloy; a copper-aluminum-nickel (CuAlNi) alloy (e.g., 14/14.5 wt. % Al and 3/4.5 wt. % Ni); a copper-zinc (CuZn) alloy (e.g., 38.5/41.5 wt. % Zn); a copper-tin (CuSn) alloy (e.g., approximately 15 at. % Sn); a copper-zinc-aluminum (CuZnAI) alloy; a copper-zinc-silicon (CuZnSi) alloy; a copper-zinc-tin (CuZnSn) alloy; a copper-manganese alloy (e.g., 5/35 at. % Cu); a gold-cadmium (AuCd) alloy (e.g., 46.5/50 at. % Cd); a silver-cadmium (AgCd) alloy (e.g., 44/49 at. % Cd); an iron-platinum (FePt) alloy (e.g., approximately 25 at. % Pt); an iron-manganese-silicon (FeMnSi) alloy (e.g., approximately 25 at. % Pt); a cobalt-nickel-aluminum (CoNiAl) alloy; a cobalt-nickel-gallium (CoNiGa) alloy; or a titanium-palladium (TiPd) alloy.
SMMs can also include shape-memory composites (SMC) and shape-memory hybrids (SHC). SMCs and SMHs are dual component systems that include at least one SMM integrated with conventional materials. Exemplary conventional materials include those useful for preparing wound care dressings, such as any described herein and include, e.g., alginate, benzyl hyaluronate, carboxymethylcellulose, cellulose acetate, chitosan, collagen, dextran, epoxy, gelatin, hyaluronic acid, hydrocolloids, nylon (e.g., nylon 6 or PA6), pectin, poly (3-hydroxyl butyrate-co-poly (3-hydroxyl valerate), polyacrylate (PA), polyacrylonitrile (PAN), polybenzimidazole (PI31), polycarbonate (PC), polycaprolactone (PCL), polyester (PE), polyethylene glycol (PEG), polyethylene oxide (PEO), PEO/polycarbonate/polyurethane (PEO/PC/PU), poly(ethylene-co-vinyl acetate) (PEVA), PEVA/polylactic acid (PEVA/PLA), poly (ethylene terephthalate) (PET), PET/poly (ethylene naphthalate) (PET/PEN) polyglactin, polyglycolic acid (PGA), polyglycolic acid/polylactic acid (PGA/PLA), polyimide (PI), polylactic acid (PLA), poly-L-lactide (PLLA), PLLA/PC/polyvinylcarbazole (PLLA/PC/PVCB), poly ((3-malic acid)-copolymers (PMLA), polymethacrylate (PMA), poly (methyl methacrylate) (PMMA), polystyrene (PS), polyurethane (PU), poly (vinyl alcohol) (PVA), polyvinylcarbazole (PVCB), polyvinyl chloride (PVC), polyvinylidenedifluoride (PVDF), polyvinylpyrrolidone (PVP), silicone, rayon, or combinations thereof.
Exemplary SMCs include dual component systems including SMM materials in contact with conventional materials, such that the conventional material applies a force to bend the SMM absent an external stimulus. Upon the addition of an external stimulus, the SMM changes shape, thus overcoming the force applied from the conventional material. The resulting shape transition moves both the SMM and conventional components. In addition, SMHs exhibit the characteristic shape transitions of SMM but are constructed from conventional materials (e.g., non-shape-memory materials). Exemplary SMHs include dual region plastic materials constructed of two conventional polymers layers, where the material bends in response to temperature changes due to the difference in thermal expansion between the two plastic layers. Additional exemplary SMC and SHC materials can be found in, e.g., in Huang et al., “Shape memory materials,” Materials Today 13:54-64 (2010), which is hereby incorporated by reference in its entirety.
Thermal-Responsive Materials
Thermal-responsive materials can change their physical and chemical properties upon changes in temperature. The transition temperature is the temperature at which the polymer's characteristics change and includes a lower critical solution temperature (LOST) or an upper critical solution temperature (UCST). A common, exemplary response to temperature change is a transition in the hydrophilic/hydrophobic character of the material. A transition to a more hydrophobic state results from changes in the polymer's ability to hydrogen bond with the surrounding environment (e.g., a solvent or solution). For a thermal-responsive polymer dissolved in solution, the temperature response can result in a transition in the polymer's conformation and solvent interaction. This transition includes an expanded state with extensive solvent interaction and a contracted state with limited solvent interaction. In the contracted state, the thermal-responsive polymer will become insoluble and precipitate from solution.
The same above-described transition can occur in other forms (e.g., in gels, such as in hydrogels in which the cross-linked polymer is swollen by a solvent, or in copolymers). Upon exposure to a temperature transition, the conformation of the polymer network changes, thus resulting in reduced solvent interactions and causing a reduction in the gel's volume. Often the transition temperature is independent of the polymer's molecular weight. The transition temperature can be modified with changes to the solvent system. For example, the addition of cosolvents or salts can increase or decrease the transition temperature. For copolymers, the transition temperature in aqueous environments is generally decreased with the addition of more hydrophobic co-monomers or polymer modifying groups. Alternatively, the transition temperature is generally increased by the addition of more hydrophilic co-monomers or polymer modifying groups.
Exemplary thermal-responsive materials include poly-N-isopropylacrylamide (poly-NIPAAm, LCST at 32-37° C.); poly-N-vinylcaprolactam (LCST at 25-35° C.); poly-N,N-diethylacrylamide (LCST at 25¬32° C.); other polyalkylacrylamides and co-polymers of polyalkylacrylamides; polyethylene glycol; polyethylene oxide (PEO, LCST at about 85° C.); polypropylene oxide (FPO); polymethylvinyl ether (LCST at 34-38° C.); and PEO-PPO copolymers. Exemplary thermal-responsive gels or hydrogels include copolymer networks of include poly-N-isopropylacrylamide, poly-N-vinylcaprolactam, poly-N,N-diethylacrylamide, and other polyalkylacrylamides with a cross-linker, such as methylene bisacrylamide. Such thermal-responsive materials can be provided in any form, such as heat shrink films.
pH-Responsive Materials
pH-responsive materials can change their physical and chemical properties upon changes in pH. A transition can arise from increased charge density resulting from protonation or deprotonation of a polymer or from decreased charge density resulting from neutralization of the polymer. In general, increasing the charge density results in increased hydrophilicity, which in turn promotes interactions with water, polar solvents, or salts. Decreasing charge density typically makes the polymer more hydrophobic and reduces the interactions with water, polar solvents, and salts.
The nature of the pH transition results from the type of acid/base functionalities present in the material. For example, the presence of amine functionalities (e.g., moieties with a high pKa) results in higher charge densities as the pH decreases and neutralization of the charge as the pH increases. Conversely, the presence of carboxylic acid functionalities (e.g. moieties with a low pKa) results in higher charge densities as the pH increases and neutralization of the charge as the pH decreases. For a pH-responsive polymer in solution, a transition from a higher charge density to a lower charge density (e.g., neutralization of charge) can result in the polymer becoming insoluble and precipitating from solution. An insoluble pH-responsive polymer can dissolve into water as the charge density is increased (e.g. increasing pH for a carboxylic acid moiety containing polymer). The same pH-response transition can occur in numerous forms, such as gels or hydrogels. Typically, an increasing charge density causes the gel network to swell with water, polar solvents, or salts, thus expanding the gel's volume. Conversely, the neutralization of charge results in a reduction of the gel volume due to the elimination of water, polar solvents or salts from the network.
Exemplary pH-responsive polymers include polyacrylic acid, polymethacrylic acid, and methacrylic acid/methyl methacrylate copolymers (Eudragit®, Evonik Industries AG); copolymers of polyacrylic acid and polyvinyl alcohol (PAA/PVA); carboxylic acid derivatives of styrene; derivatives of cellulose such as carboxymethylethylcellulose, cellulose acetate-phthalate and diethylaminoethyl cellulose; diethylaminoethyl methacrylate/methyl methacrylate or butyl methacrylate copolymers (e.g., insoluble at pH 7, soluble at acidic pH); polypyridine; polyallylamine, polyvinylamine, chitosan, and other polyamines; as well as N-dimethylaminoethyl methacrylate, biodegradable copolymers of N,N-dimethylacrylamide, N-tert-butyl acrylamide and N-methylacryoylglycylglycine p-nitrophenyl ester. Exemplary pH-responsive gels or hydrogels include methacrylic acid/methyl methacrylate polymer networks crosslinked with a bifunctional methacrylate, such as 1,4-butanediol dimethacrylate, carboxylic acid derivatives of styrene crosslinked with divinylbenzene; cellulose derivatives crosslinked with multifunctional cross-linking agents such as butanediol diglycidylether; as well as copolymers of polyacrylic acid and polyvinyl alcohol cross-linked with a divinyl group such as 1,4-butanediol dimethacrylate. Exemplary pH-sensitive materials are found, e.g., in Galaev et al., Russian Chem. Reviews 64: 471-489 (1995), which is hereby incorporated by reference in its entirety.
Light-Responsive Materials
Light-responsive materials can change their physical and chemical properties upon exposure to electromagnetic radiation. Typically, moieties within the polymer structure undergo a change in response to light of a particular energy. The light provides energy for the moiety to overcome activation energy barriers and transition into a different conformation or state. For example, a copolymer incorporating an azobenzene chromophore has a lower dipole moment (e.g., is less polar) in the trans conformation around the azo double bond. The azobenzene moiety provides a light sensitive “switch,” which provides the response to external stimulus. Upon irradiation with light, the double bond can isomerizes to the cis conformation, thus increasing the dipole moment (e.g., making the polymer more polar). The increase in polarity can result in increased solubility in polar solvents. This phenomenon is observed with a dimethylacrylamide-4-phenylazophenylacrylate (7.5 mol %) copolymer. At a temperature slightly above the LOST, the solution is generally cloudy. However, upon UV irradiation, the copolymer's LCST is reduced below the environmental temperature and the solution becomes clear as the copolymer dissolves. Exemplary light-sensitive polymers are found, e.g., in Galaev et al., Russian Chem. Reviews 64:471-489 (1995), which is hereby incorporated by reference in its entirety.
Light-responsive polymers include those having one or more of the following light-responsive switches: cinnamic acid, cinnamylidene acetic acid, azobenzene chromophores (e.g., 4-phenylazobenzene), triarylmethylcyanide, stilbene, or quinone-methide moieties.
Moisture-Responsive Materials
Moisture-responsive materials can change their physical and chemical properties upon a change in the environmental humidity or water content. This transition generally involves an increasing or decreasing association with other components in the medium following exposure to water. Essentially, water displaces or increases the volume of the existing medium thus causing changes commiserate with the polymer's hydrophilicity. For example, the grafted polymer, polymethacrylic acid-graft-polyethylene glycol, is collapsed in solutions with a high ethanol/water ratio. Upon addition of water the polymer swells thus increasing the polymers porosity. This volumetric change enables the release of therapeutic compounds after contacting the polymer containing therapeutic compounds with a mucus membrane. This exemplary moisture-sensitive polymer is found in de las Heras Alarcon et al., Chem. Soc. Rev. 34:276-285 (2005), which is hereby incorporated by reference in its entirety.
Exemplary moisture-sensitive polymers include copolymers of ionic monomers, such asacrylamidopropane sulfonic acid sodium salt with neutral monomers, such as acrylamide; pH sensitive polymers, as described above with high charge density; and grafted polymers, such as polymethacrylic acid-graft-polyethylene glycol.
Solvent-Responsive or Chemical Exposure-Responsive Materials
Solvent-responsive materials can change their physical and chemical properties upon a change in the solvent or chemical content of the surrounding medium or environment. Similar to the moisture-responsive materials described above, solvent or chemical exposure-responsive materials possess a transition involving an increasing or decreasing association with other components in the medium following exposure to a solvent or chemical. Generally, the solvent responds to displaces or increases the volume of the existing medium, thus causing changes consistent with the polymer's relative compatibility between the exposed solvent and the existing medium. The solvent-responsive material can be a polymer composite with another material or a modified non-polymeric material.
En exemplary chemical-responsive material is a combination of activated carbon and polyaniline were formed into a composite structure or chemiresistive detector. Adsorption of biogenic amines causes a response in the polymer component, which changes the resistance of the composite and yields an electrical signal indicating the presence of the analyte. This exemplary solvent-sensitive polymer composite is found in patent number EP1278061B1, which is hereby incorporated by reference in its entirety
Exemplary solvent or chemical exposure-responsive materials include a polymer/carbon blackcomposite, polyaniline/carbon black composite, gold/para-substituted thiophenol, gold clusters encapsulated with octanethiol, and a dendrimer of poly(amidoamine).
Electric Field-Responsive Materials
Electric field-responsive materials can change their physical and chemical properties upon changes to the applied electric field. The electric field-responsive materials can be metal or a composite material including a polymer and metal. In general, the electric field stimulates a electric field sensitive component or electric “switch.” The polymer component of electric field-sensitive composites can be made from any polymer with the desired polymer properties.
Electric field-responsive materials include those having one or more of the following switches: carbon black, carbon nanotube, metallic Ni powder, short carbon fibers (SCFs), or super-paramagnetic nanoparticles (e.g., magnetite nanoparticles). Electric field-responsive materials can optionally include any composite or material described herein.
Magnetic Field-Responsive Materials
Magnetic field-responsive materials can change their physical properties upon changes to the applied magnetic field. The magnetic field-responsive materials can be metal or metal polymer composite materials. In general, the magnetic field stimulates a magnetic field sensitive component or magnetic “switch.” The polymer component of magnetic field-sensitive composites can be made from any polymer with the desired polymer properties.
Exemplary magnetic field-responsive materials or magnetic switches include magnetite, poly [aniline-co-N-(1-butyric acid)]aniline/iron oxide, polylactide/nanocrystalline magnetite, maghemite, cobalt ferrite, carbonyl iron, ferromagnetic shape-memory alloy, magnetic nanoparticles (e.g., such as iron, cobalt, or iron oxide (e.g., Fe3O4)), spinel ferrimagnets (e.g., such as CoFe2O4 and MnFe2O4), and alloys (e.g., CoPt3 and FePt). Exemplary polymers for magnetic field-responsive composites include any polymer described herein, e.g., high molecular weight polyacrylic acid, polyethylene glycol, poly(2-vinyl-N-methylpyridinium iodide), polystyrene, polyethyleneimine, and block copolymers of polystyrene, such as poly(styrene-b-butadiene-b-styrene). Exemplary magnetic field-sensitive polymers are found, e.g., in Dai et al., Chem. Soc. Rev. 39:4057-4066 (2010), which is hereby incorporated by reference in its entirety.
Actuator-Embedded Materials
Actuator-embedded materials can include one or more micro electro-mechanical systems actuators (or MEMS actuators) to change their physical properties upon exposure to one or more stimuli. Such actuator-embedded materials can result in mechanical, hydraulic, and/or pneumatic control of compression and/or expansion of the device. In some embodiments, the actuator-embedded materials include one or more actuators in combination with one or more polymers (e.g., any described herein, including polyvinylidenedifluoride, polyimide, polyester, rayon, epoxy, or combinations thereof). Exemplary actuators includes those made from one or more carbon nanotubes (e.g., single-walled carbon nanotube composites having a piezoelectric effect); one or more piezoceramic actuators (e.g., including lead magnesium niobate (PMN), and optionally having one or more interdigitated electrodes, or one or more Pb(ZrxTi1,)03(PZT) materials (e.g., Ceramic B, PZT-2, PZT-4, PZT-5H, PZT-5A, PZT-4S, or PZT-8M, available from MTC Electro Ceramics, Berkshire, England)); one or more multilayered actuators (e.g., a PZT-based actuator, such as RAINBOW (Reduced And Internally Biased Oxide Wafer); a thin-layered piezoelectric composite material, such as THUNDER (Thin Layer Composite Unimorph ferroelectric DrivER and sensor); a laminate material including piezofibers, interdigitated electrodes, and a polymer (e.g., PVDF or polyimide, such as a Kapton® film), such as an AFC (Active Fiber Composite) developed by MIT University, USA; a macro-fiber composite including uniaxially aligned piezofibers in a polymer matrix, such as LaRC-MFC™ (NASA-Langley Research Center Macro-Fiber Composite); or a composite actuator including a carbon fiber composite layer with near-zero coefficient of thermal expansion (CTE), a PZT ceramic wafer, and a glass/epoxy layer, such as LIPCA (Lightweight Piezo-Composite Actuator)); one or more optical fibers (e.g., quartz-type and single-mode optical fibers, optionally embedded in an epoxy matrix); one or more piezopolymeric films; one or more piezoplates (e.g., a lead zirconate titanate plate that is optionally nickel-plated, e.g., PSI-5A4E or PSI-5H4E, available from Piezo Systems, Inc., Woburn, MA); one or more piezofibers (e.g., one or more carbon fibers and/or glass fibers, as well as composites thereof); one or more shape-memory polymers (e.g., any described herein); or one or more shape-memory alloys (e.g., any described herein, such as a NiTi alloy).
Exemplary actuator-embedded materials include carbon nanotubes in combination with polyvinylidenedifluoride (PVDF, optionally as a melt-blended or electrospun composite); carbon nanotubes in combination with polyimide (PI, optionally as a melt-blended or electrospun composite); unidirectional carbon fiber pre-impregnated sheets, such as XN-50A-RS3C, available from TenCate Corp., Nijverdal, Netherlands; Terfenol-D®, a magnetorestrictive material having terbium, iron, and dysprosium (available from Etrema Products Inc., Ames, IA); a thermally actuated composite incombination with a microelectronic substrate, such as those described in U.S. Pat. No. 6,211,598, which is hereby incorporated by reference in its entirety; a composite material including a nickel-tin shape-memory alloy (e.g., Nitinol™) in a thin film; or a magnetorestrictive composite including layers of Tb—Fe, polyimide, and Sm—Fe. Further exemplary materials are provided in U.S. Pat. No. 6,211,598 and International Pub. Nos. WO 2007/024038, each of which is incorporated by reference in its entirety.
Unstretched Materials
The dressings of the invention can include one or more unstretched materials. Such unstretched materials include those having sufficient rigidity to hinder stretching and those having one or more stretchable polymers that are not stretched prior to affixing to a skin region. Exemplary unstretchedmaterials include Tegader™, available from 3M, St. Paul, MN, which can optionally be stretched after affixing to a skin region.
Unstretched materials have not been dimensionally altered and are in a stable dimensional state. Conversely, a stretched material has an unstable dimensional state because the material has been dimensionally altered within the material's elastic region by a force. An unstretched material can also be highly rigid or cross-linked (e.g., highly resistant to stretching). Alternatively, an unstretched material can be a naïve material, which can be stretched in subsequent use.
Exemplary unstretched materials include any polymer or material described herein, a conventional material(s) (e.g., as described herein), permanent adhesive(s), highly cross-linked polymeric material(s), and material(s) with high rigidity or hardness and low ductility (e.g., carboxymethylcellulose, gelatin, pectin, alginate, polyurethane, polymethacrylate, polyvinylpyrrolidone, nylon, polyethylene, polyacrylate, collagen, silicone, polyglycolic acid/polylactic acid, polyglycolic acid, polyglactin, benzyl hyaluronate, or combinations thereof, in any useful form, such as a film, bandage, gel, or hydrogel).
Adhesive Materials
An adhesive can be used within the dressing (e.g., as in the adhesive layer) or used in combination with any method described herein to promote skin tightening.
The adhesive can be a pressure-sensitive adhesive (PSA). The properties of pressure sensitive adhesives are governed by three parameters, tack (initial adhesion), peel strength (adhesion), and shear strength (cohesion). Pressure-sensitive adhesives can be synthesized in several ways, including solvent-borne, water-borne, and hot-melt methods. Tack is the initial adhesion under slight pressure and short dwell time and depends on the adhesive's ability to wet the contact surface. Peel strength is the force required to remove the PSA from the contact surface. The peel adhesion depends on many factors, including the tack, bonding history (e.g. force, dwell time), and adhesive composition. Shear strength is a measure of the adhesive's resistance to continuous stress. The shear strength is influenced by several parameters, including internal adhesion, cross-linking, and viscoelastic properties of the adhesive. Permanent adhesives are generally resistant to debonding and possess very high peel and shear strength.
Exemplary adhesives include a biocompatible matrix (e.g., those including at least one of collagen (e.g., a collagen sponge), low melting agarose (LMA), polylactic acid (PLA), and/or hyaluronicacid (e.g., hyaluranon); a photosensitizer (e.g., Rose Bengal, riboflavin-5-phosphate (R-5-P), methylene blue (MB), N-hydroxypyridine-2-(1H)-thione (N-HTP), a porphyrin, or a chlorin, as well as precursors thereof); a photochemical agent (e.g., 1,8 naphthalimide); a synthetic glue (e.g., a cyanoacrylate adhesive, a polyethylene glycol adhesive, or a gelatin-resorcinol-formaldehyde adhesive); or a biologic sealant (e.g., a mixture of riboflavin-5-phosphate and fibrinogen, a fibrin-based sealant, an albumin-based sealant, or a starch-based sealant). In particular embodiments, the adhesive is biodegradable.
Exemplary pressure-sensitive adhesives include natural rubber, synthetic rubber (e.g., styrene-butadiene and styrene-ethylene copolymers), polyvinyl ether, polyurethane, acrylic, silicones, and ethylene-vinyl acetate copolymers. A copolymer's adhesive properties can be altered by varying the composition (via monomer components) changing the glass transition temperature (Tg) or degree of cross-linking. In general, a copolymer with a lower Tg is less rigid and a copolymer with a higher Tg is more rigid. The tack of PSAs can be altered by the addition of components to alter the viscosity or mechanical properties. Exemplary pressure sensitive adhesives are described in Czech et al., “Pressure-Sensitive Adhesives for Medical Applications,” in Wide Spectra of Quality Control, Dr. Isin Akyar (Ed., published by InTech), Chapter 17 (2011), which is hereby incorporated by reference in its entirety
In one exemplary technique, a photosensitizer is applied to the tissue (e.g., Rose Bengal (RB) at concentration of less than 1.0% weight per volume in a buffer, e.g., phosphate buffered saline to form a skin tissue-RB complex), and then the tissue is irradiated with electromagnetic energy to produce a seal (e.g., irradiated at a wavelength of at least 488, at less than 2000 J/cm2, and/or at less than 1.5 W/cm2, e.g., about 0.6 W/cm2). This exemplary technique is described in U.S. Pat. No. 7,073,510, which is incorporated by reference in its entirety. In another exemplary technique, a laser can be used for tissue welding. In yet another exemplary technique, a photochemical agent is applied to the tissue, and then the tissue is irradiated with visible light to produce a seal.
Therapeutic Agents
The dressings and methods of the invention can include one or more useful therapeutic agents. Exemplary agents include one or more growth factors (e.g., vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-(3), fibroblast growth factor (FGF), epidermal growth factor (EGF), and keratinocyte growth factor); one or more stem cells (e.g., adipose tissue-derived stem cells and/or bone marrow-derived mesenchymal stem cells); steroids (for example, steroids to prevent edema), agents which prevent post-inflammatory skin hyperpigmentation (e.g., hydroquinone, azelaic acid, kojic acid, mandelic acid, or niacinamide); one or more analgesics (e.g., paracetamol/acetaminophen, aspirin, a non-steroidal anti-inflammatory drug, as described herein, a cyclooxygenase-2-specific inhibitor, as described herein, dextropropoxyphene, co-codamol, an opioid (e.g., morphine, codeine, oxycodone, hydrocodone, dihydromorphine, pethidine, buprenorphine, tramadol, or methadone), fentanyl, procaine, lidocaine, tetracaine, dibucaine, benzocaine, p-butylaminobenzoic acid 2-(diethylamino) ethyl ester HCl, mepivacaine, piperocaine, dyclonine, or venlafaxine); one or more antibiotics (e.g., cephalosporin, bactitracin, polymyxin B sulfate, neomycin, bismuth tribromophenate, or polysporin); one or more antifungals (e.g., nystatin); one or more anti-inflammatory agents (e.g., a non-steroidal anti-inflammatory drug (NSAID, e.g., ibuprofen, ketoprofen, flurbiprofen, piroxicam, indomethacin, diclofenac, sulindac, naproxen, aspirin, ketorolac, or tacrolim us), a cyclooxygenase-2-specific inhibitor (COX-2 inhibitor, e.g., rofecoxib (Vioxx®), etoricoxib, and celecoxib (Celebrex®)), a glucocorticoid agent, a specific cytokine directed at T lymphocyte function), a steroid (e.g., a corticosteroid, such as a glucocorticoid (e.g., aldosterone, beclometasone, betamethasone, cortisone, deoxycorticosterone acetate, dexamethasone, fludrocortisone acetate, hydrocortisone, methylprednisolone, prednisone, prednisolone, or triamcinolone) or a mineralocorticoid agent (e.g., aldosterone, corticosterone, or deoxycorticosterone)), or an immune selective anti-inflammatory derivative (e.g., phenylalanine-glutamine-glycine (FEG) and its D-isomeric form (feG))); one or more antimicrobials (e.g., chlorhexidine gluconate, iodine (e.g., tincture of iodine, povidone-iodine, or Lugol's iodine), or silver, such as silver nitrate (e.g., as a 0.5% solution), silver sulfadiazine (e.g., as a cream), or Ag+ in one or more useful carriers (e.g., an alginate, such as Acticoat® including nanocrystalline silver coating in high density polyethylene, available from Smith & Nephew, London, U.K., or Silvercel® including a mixture of alginate, carboxymethylcellulose, and silver coated nylon fibers, available from Systagenix, Gatwick, U.K.; a foam (e.g., Contreet® Foam including a soft hydrophilic polyurethane foam and silver, available from Coloplast A/S, Humlebaak, Denmark); a hydrocolloid (e.g., Aquacel® Ag including ionic silver and a hydrocolloid, available from Conva Tec Inc., Skillman, NJ); or a hydrogel (e.g., Silvasorb® including ionic silver, available from Medline Industries Inc., Mansfield, MA)); one or more antiseptics (e.g., an alcohol, such as ethanol (e.g., 60-90%), 1-propanol (e.g., 60-70%), as well as mixtures of 2-propanol/isopropanol; boric acid; calcium hypochlorite; hydrogen peroxide; manuka honey and/or methylglyoxal; a phenol (carbolic acid) compound, e.g., sodium 3,5-dibromo-4-hydroxybenzene sulfonate, trichlorophenylmethyl iodosalicyl, or triclosan; a polyhexanide compound, e.g., polyhexamethylene biguanide (PHMB); a quaternary ammonium compound, such as benzalkonium chloride (BAC), benzethonium chloride (BZT), cetyl trimethylammonium bromide (CTMB), cetylpyridinium chloride (CPC), chlorhexidine (e.g., chlorhexidine gluconate), or octenidine (e.g., octenidine dihydrochloride); sodium bicarbonate; sodium chloride; sodium hypochlorite (e.g., optionally in combination with boric acid in Dakin's solution); or a triarylmethane dye (e.g., Brilliant Green)); one or more antiproliferative agents (e.g., sirolimus, tacrolimus, zotarolimus, biolimus, or paclitaxel); one or more emollients; one or more hemostatic agents (e.g., collagen, such as microfibrillar collagen, chitosan, calcium-loaded zeolite, cellulose, anhydrous aluminum sulfate, silver nitrate, potassium alum, titanium oxide, fibrinogen, epinephrine, calcium alginate, poly-N-acetyl glucosamine, thrombin, coagulation factor(s) (e.g., II, V, VII, VIII, IX, X, XI, XIII, or Von Willebrand factor, as well as activated forms thereof), a procoagulant (e.g., propyl gallate), an anti-fibrinolytic agent (e.g., epsilon aminocaproic acid or tranexamic acid), and the like); one or more procoagulative agents (e.g., any hemostatic agent described herein, desmopressin, coagulation factor(s) (e.g., II, V, VII, VIII, IX, X, XI, XIII, or Von Willebrand factor, as well as activated forms thereof), procoagulants (e.g., propyl gallate), antifibrinolytics (e.g., epsilon aminocaproic acid), and the like); one or more anticoagulative agents (e.g., heparin or derivatives thereof, such as low molecular weight heparin, fondaparinux, oridraparinux; an anti-platelet agent, such as aspirin, dipyridamole, ticlopidine, clopidogrel, or prasugrel; a factor Xa inhibitor, such as a direct factor Xa inhibitor, e.g., apixaban or rivaroxaban; a thrombin inhibitor, such as a direct thrombin inhibitor, e.g., argatroban, bivalirudin, dabigatran, hirudin, lepirudin, or ximelagatran; or a coumarin derivative or vitamin K antagonist, such as warfarin (coumadin), acenocoumarol, atromentin, phenindione, or phenprocoumon); one or more immune modulators, including corticosteroids and non-steroidal immune modulators (e.g., NSAIDS, such as any described herein); one or more proteins; or one or more vitamins (e.g., vitamin A, C, and/or E).
For the skin tightening methods described herein, the use of anticoagulative and/or procoagulative agents may be of particular relevance. For instance, by controlling the extent of bleeding and/or clotting in the incisions and/or excisions, the skin tightening effect can be more effectively controlled. Thus, in some embodiments, the methods and devices herein include one or more anticoagulative agents, one or more procoagulative agents, one or more hemostatic agents, or combinations thereof. In particular embodiments, the therapeutic agent controls the extent of bleeding and/or clotting in the treated skin region, including the use one or more anticoagulative agents (e.g., to inhibit clot formation prior to skin healing or slit/hole closure) and/or one or more hemostatic or procoagulative agents.
Kits, Optionally Including One or More Applicators
Also described herein are kits for skin tightening or for treating diseases, disorders, and conditions that would benefit from skin restoration or tightening. Accordingly, the present invention includes kits having one or more devices in combination with one or more applicators, as well kits having a combination of two or more devices, where at least one device is a tunable dressing as described herein.
The kit includes a device, such as any tunable dressing described herein, and any other useful component. In some embodiments, the kit includes a device (e.g., a tunable dressing) and an applicator. The applicator can include a frame or any structure configured to affix a device to the skin region, where the frame or structure is optionally disposable. In general, each device or tunable dressing is configured to be affixed to a skin region, and the applicator can be configured to assist in the affixation of such a device. In some embodiments, the applicator maintains the device in an unstretched state to allow for affixing a device having an unstretched layer. In other embodiments, the applicator holds the device to allow for aligning, positioning, and/or placing the device on the desired skin region. In yet other embodiments, the applicator is configured to allow for affixing a tunable dressing immediately after or shortly after forming one or more incisions or excisions in the skin region. In such an embodiment, the applicator is configured to releasably attach to an apparatus for making such an incision or excision (e.g., an apparatus including one or more blades and/or one or more tubes or a microablation tool, such as any described herein). The applicator can be of any useful shape and/or material (e.g., any material or polymer described herein). In some embodiments, the applicator is a frame that provides sufficient support to the device or tunable dressing and/or provides a sterile method to affix the device or tunable dressing. In particular embodiments, the frame includes a rigid plate having one or more view ports (e.g., one or more transparent windows) to allow for positioning of the device. In some embodiments, the frame is structurally configured to attach to an apparatus for making one or more incisions and/or excisions and to release a device (e.g., a tunable dressing) after making such an incision or excision.
In other embodiments, the applicator includes a liner layer having one or more handles, where the liner layer is attached to the proximal surface of a tunable dressing. The handles allow for positioning the dressing over the treated skin region. In some embodiments, the handles are configured to be detached from the dressing immediately prior to or after affixation. In some embodiments, the applicator includes a releasing layer. Exemplary applicators are provided in U.S. Pub. Nos. 2012/0226306 and 2012/0226214, where each is hereby incorporated by reference in its entirety.
There may be a plurality of devices (e.g., tunable dressings) in a kit. Within the kit, the tunable dressings may be packaged individually (e.g., in sets of two or more). In some embodiments, each tunable dressing includes an applicator, where the dressing and the applicator are configured together in one package. In other embodiments, the kit includes one or more tunable dressings in combination with one or more applicators, where each of the dressing(s) and applicator(s) is individually packaged. The dressing(s) and/or applicator(s) are packaged such that they remain sterile until use. In certain embodiments, the dressing(s) and/or applicator(s) are packaged in plastic sheaths. Further, to prevent contamination of the skin region, the dressing(s) and/or applicator(s) are preferably provided for as disposable and/or single-use items.
The kit can include a tunable dressing in combination with any other device or apparatus described herein (e.g., a device or apparatus for forming one or more incisions or excisions in a skin region). In some embodiments, the other device or apparatus includes one or more blades and/or one or more needles. In other embodiments, the other device or apparatus includes a microablation tool. Exemplary microablation tools include a fractional laser microablation tool, a fractional radiofrequency microablation tool, or a fractional ultrasonic microablation tool.
The kit can include any other useful components. Exemplary components include instructions on how to use the device(s), an air blower, a heat gun, a heating pad, one or more therapeutic agents (e.g., any described herein, such as an anticoagulative and/or procoagulative agent, and optionally in combination with a useful dispenser for applying the therapeutic agent, such as a brush, spray, film, ointment, cream, lotion, or gel), one or more wound cleansers (e.g., including any antibiotic, antimicrobial, or antiseptic, such as those described herein, in any useful form, such as a brush, spray, film, ointment, cream, lotion, or gel), one or more debriding agents, and/or other suitable or useful materials.
Methods for Treating Skin Regions
The present invention relates to methods and devices that can be applied to treated skin regions. In particular embodiments, these regions are treated with one or more procedures to improve skin appearance. Accordingly, the devices, dressings, and methods herein can be useful for skin rejuvenation (e.g., removal of pigment, tattoo removal, veins (e.g., spider veins or reticular veins), and/or vessels in the skin) or for treating acne, allodynia, blemishes, ectopic dermatitis, hyperpigmentation, hyperplasia (e.g., lentigo or keratosis), loss of translucency, loss of elasticity, melasma (e.g., epidermal, dermal, or mixed subtypes), photodamage, rashes (e.g., erythematous, macular, papular, and/or bullous conditions), psoriasis, rhytides (or wrinkles, e.g., crow's feet, age-related rhytides, sun-related rhytides, or heredity-related rhytides), sallow color, scar contracture (e.g., relaxation of scar tissue), scarring (e.g., due to acne, surgery, or other trauma), skin aging, skin contraction (e.g., excessive tension in the skin), skin irritation/sensitivity, skin laxity (e.g., loose or sagging skin or other skin irregularities), striae (or stretch marks), vascular lesions (e.g., angioma, erythema, hemangioma, papule, port wine stain, rosacea, reticular vein, or telangiectasia), or any other unwanted skin irregularities.
Such treatments can be include any parts of the body, including the face (e.g., eyelid, cheeks, chin, forehead, lips, or nose), neck, chest (e.g., as in a breast lift), arms, legs, and/or back. Accordingly, the devices on the invention can be arranged or configured to be amenable to the size or geometry of different body regions. Such arrangements and configurations can include any useful shape (e.g., linear, curved, or stellate), size, and/or depth.
In one exemplary procedure, a plurality of tissue portions are incised into or excised from a skin region in a subject (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, or more tissue portions, such as between about 2 and 100 tissue portions (e.g., between 2 and 10, 2 and 15, 2 and 20, 2 and 25, 2 and 30, 2 and 35, 2 and 40, 2 and 45, 2 and 50, 2 and 75, 5 and 10, 5 and 15, 5 and 20, 5 and 25, 5 and 30, 5 and 35, 5 and 40, 5 and 45, 5 and 50, 5 and 75, 5 and 100, 10 and 20, 10 and 25, 10 and 30, 10 and 35, 10 and 40, 10 and 45, 10 and 50, 10 and 75, 10 and 100, 15 and 20, 15 and 25, 15 and 30, 15 and 35, 15 and 40, 15 and 45, 15 and 50, 15 and 75, 15 and 100, 20 and 25, 20 and 30, 20 and 35, 20 and 40, 20 and 45, 20 and 50, 20 and 75, 20 and 100, 25 and 30, 25 and 35, 25 and 40, 25 and 45, 25 and 50, 25 and 75, 25 and 100, 30 and 35, 30 and 40, 30 and 45, 30 and 50, 30 and 75, 30 and 100, 35 and 40, 35 and 45, 35 and 50, 35 and 75, 35 and 100, 40 and 45, 40 and 50, 40 and 75, 40 and 100, 50 and 75, or 50 and 100)). Such tissue portions can be included in any useful geometric, non-geometric, or random array (e.g., such as those described herein for an array of tubes and/or blades). Such tissue portions can have any useful dimension that promotes wound or skin healing. Non-limiting dimensions of a tissue portion includes at least one dimension that is less than about 2.0 mm (e.g., less than or equal to about 1.5 mm, 1 mm, 0.75 mm, 0.5 mm, 0.3 mm, 0.2 mm, 0.1 mm, 0.075 mm, 0.05 mm, or 0.025 mm) or between about 0.025 mm and 2.0 mm (e.g., between about 0.025 mm and 1.5 mm, 0.025 mm and 1.0 mm, 0.025 mm and 0.75 mm, 0.025 mm and 0.5 mm, 0.025 mm and 0.3 mm, 0.025 mm and 0.2 mm, 0.025 mm and 0.1 mm, 0.025 mm and 0.075 mm, 0.025 mm and 0.05 mm, 0.05 mm and 2.0 mm, 0.05 mm and 1.5 mm, 0.05 mm and 1.0 mm, 0.05 mm and 0.75 mm, 0.05 mm and 0.5 mm, 0.05 mm and 0.3 mm, 0.05 mm and 0.2 mm, 0.05 mm and 0.1 mm, 0.05 mm and 0.075 mm, 0.075 mm and 2.0 mm, 0.075 mm and 1.5 mm, 0.075 mm and 1.0 mm, 0.075 mm and 0.75 mm, 0.075 mm and 0.5 mm, 0.075 mm and 0.3 mm, 0.075 mm and 0.2 mm, 0.075 mm and 0.1 mm, 0.1 mm and 2.0 mm, 0.1 mm and 1.5 mm, 0.1 mm and 1.0 mm, 0.1 mm and 0.75 mm, 0.1 mm and 0.5 mm, 0.1 mm and 0.3 mm, 0.1 mm and 0.2 mm, 0.2 mm and 2.0 mm, 0.2 mm and 1.5 mm, 0.2 mm and 1.0 mm, 0.2 mm and 0.75 mm, 0.2 mm and 0.5 mm, 0.2 mm and 0.3 mm, 0.3 mm and 2.0 mm, 0.3 mm and 1.5 mm, 0.3 mm and 1.0 mm, 0.3 mm and 0.75 mm, 0.3 mm and 0.5 mm, 0.5 mm and 2.0 mm, 0.5 mm and 1.5 mm, 0.5 mm and 1.0 mm, 0.5 mm and 0.75 mm, 0.75 mm and 2.0 mm, 0.75 mm and 1.5 mm, or 0.75 mm and 1.0 mm).
In some embodiments, the incised or excised tissue portions forms a hole in the skin region, where the diameter or width of the hole is less than about 1.0 mm and results in a tissue portion having a diameter or width that is less than about 1.0 mm. In further embodiments, the tissue portion has a diameter or width that is less than about 1.0 mm and a length of more than about 1.0 mm (e.g., about 1.0 mm, 1.5 mm, 2.0 mm. 2.5 mm, 3.0 mm, or 3.5 mm). In particular embodiments, relatively small dimensions of the tissue portions can promote healing while minimizing the formation of scars.
In other embodiments, the incised or excised tissue portions forms a slit in the skin region, where the length or width of the slit is less than about 1.0 mm and results in a tissue portion having a length or width that is less than about 1.0 mm. In further embodiments, the tissue portion has a length or width that is less than about 1.0 mm and a length of more than about 1.0 mm (e.g., about 1.0 mm, 1.5 mm, 2.0 mm. 2.5 mm, 3.0 mm, or 3.5 mm). In particular embodiments, relatively small dimensions of the tissue portions can promote healing while minimizing the formation of scars.
The tissue portion can be of any useful shape. Exemplary shapes include cylinders (i.e., thereby forming round or elongated holes in the skin region), holes (e.g., microholes), slits (e.g., microslits), elongated strips (i.e., thereby forming elongated openings in the skin region), or other geometries including at least dimension that is less than about 1.0 mm (e.g., less than or equal to about 0.75 mm, about 0.5 mm, about 0.3 mm, about 0.2 mm, about 0.1 mm, or about 0.05 mm) or between about 0.05 mm and 1.0 mm (e.g., 0.05 mm and 0.75 mm, 0.05 mm and 0.5 mm, 0.05 mm and 0.3 mm, 0.05 mm and 0.2 mm, 0.05 mm and 0.1 mm, 0.1 mm and 1.0 mm, 0.1 mm and 0.75 mm, 0.1 mm and 0.5 mm, 0.1 mm and 0.3 mm, 0.1 mm and 0.2 mm, 0.2 mm and 1.0 mm, 0.2 mm and 0.75 mm, 0.2 mm and 0.5 mm, 0.2 mm and 0.3 mm, 0.3 mm and 1.0 mm, 0.3 mm and 0.75 mm, 0.3 mm and 0.5 mm, 0.4 mm and 1.0 mm, 0.4 mm and 0.75 mm, 0.4 mm and 0.5 mm, 0.5 mm and 1.0 mm, 0.5 mm and 0.75 mm, 0.6 mm and 1.0 mm, 0.6 mm and 0.75 mm, or 0.75 mm and 1.0 mm). In other embodiments, the incised tissue portion and/or excised tissue portion has an areal dimension (e.g., a cross-sectional dimension in the xy-plane, such as an areal dimension of a circle or non-circular (e.g., elliptical) shape) of less than about or equal to about 1.0 mm2 (e.g., less than or equal to about 0.9 mm2, 0.8 mm2, 0.7 mm2, 0.6 mm2, 0.5 mm2, 0.4 mm2, 0.3 mm2, 0.2 mm2, 0.1 mm2, 0.07 mm2, 0.05 mm2, 0.03 mm2, 0.02 mm2, 0.01 mm2, 0.007 mm2, 0.005 mm2, 0.003 mm2, 0.002 mm2, or 0.001 mm2) or between about 0.001 mm2 and 1.0 mm2 (e.g., 0.001 mm2 and 0.9 mm2, 0.001 mm2 and 0.8 mm2, 0.001 mm2 and 0.7 mm2, 0.001 mm2 and 0.6 mm2, 0.001 mm2 and 0.5 mm2, 0.001 mm2 and 0.4 mm2, 0.001 mm2 and 0.3 mm2, 0.001 mm2 and 0.2 mm2, 0.001 mm2 and 0.1 mm2, 0.001 mm2 and 0.07 mm2, 0.001 mm2 and 0.05 mm2, 0.001 mm2 and 0.03 mm2, 0.001 mm2 and 0.02 mm2, 0.001 mm2 and 0.01 mm2, 0.001 mm2 and 0.007 mm2, 0.001 mm2 and 0.005 mm2, 0.001 mm2 and 0.003 mm2, 0.001 mm2 and 0.002 mm2, 0.002 mm2 and 1.0 mm2, 0.002 mm2 and 0.9 mm2, 0.002 mm2 and 0.8 mm2, 0.002 mm2 and 0.7 mm2, 0.002 mm2 and 0.6 mm2, 0.002 mm2 and 0.5 mm2, 0.002 mm2 and 0.4 mm2, 0.002 mm2 and 0.3 mm2, 0.002 mm2 and 0.2 mm2, 0.002 mm2 and 0.1 mm2, 0.002 mm2 and 0.07 mm2, 0.002 mm2 and 0.05 mm2, 0.002 mm2 and 0.03 mm2, 0.002 mm2 and 0.02 mm2, 0.002 mm2 and 0.01 mm2, 0.002 mm2 and 0.007 mm2, 0.002 mm2 and 0.005 mm2, 0.002 mm2 and 0.003 mm2, 0.005 mm2 and 1.0 mm2, 0.005 mm2 and 0.9 mm2, 0.005 mm2 and 0.8 mm2, 0.005 mm2 and 0.7 mm2, 0.005 mm2 and 0.6 mm2, 0.005 mm2 and 0.5 mm2, 0.005 mm2 and 0.4 mm2, 0.005 mm2 and 0.3 mm2, 0.005 mm2 and 0.2 mm2, 0.005 mm2 and 0.1 mm2, 0.005 mm2 and 0.07 mm2, 0.005 mm2 and 0.05 mm2, 0.005 mm2 and 0.03 mm2, 0.005 mm2 and 0.02 mm2, 0.005 mm2 and 0.01 mm2, 0.005 mm2 and 0.007 mm2, 0.007 mm2 and 1.0 mm2, 0.007 mm2 and 0.9 mm2, 0.007 mm2 and 0.8 mm2, 0.007 mm2 and 0.7 mm2, 0.007 mm2 and 0.6 mm2, 0.007 mm2 and 0.5 mm2, 0.007 mm2 and 0.4 mm2, 0.007 mm2 and 0.3 mm2, 0.007 mm2 and 0.2 mm2, 0.007 mm2 and 0.1 mm2, 0.007 mm2 and 0.07 mm2, 0.007 mm2 and 0.05 mm2, 0.007 mm2 and 0.03 mm2, 0.007 mm2 and 0.02 mm2, 0.007 mm2 and 0.01 mm2, 0.01 mm2 and 1.0 mm2, 0.01 mm2 and 0.9 mm2, 0.01 mm2 and 0.8 mm2, 0.01 mm2 and 0.7 mm2, 0.01 mm2 and 0.6 mm2, 0.01 mm2 and 0.5 mm2, 0.01 mm2 and 0.4 mm2, 0.01 mm2 and 0.3 mm2, 0.01 mm2 and 0.2 mm2, 0.01 mm2 and 0.1 mm2, 0.01 mm2 and 0.07 mm2, 0.01 mm2 and 0.05 mm2, 0.01 mm2 and 0.03 mm2, 0.01 mm2 and 0.02 mm2, 0.03 mm2 and 1.0 mm2, 0.03 mm2 and 0.9 mm2, 0.03 mm2 and 0.8 mm2, 0.03 mm2 and 0.7 mm2, 0.03 mm2 and 0.6 mm2, 0.03 mm2 and 0.5 mm2, 0.03 mm2 and 0.4 mm2, 0.03 mm2 and 0.3 mm2, 0.03 mm2 and 0.2 mm2, 0.03 mm2 and 0.1 mm2, 0.03 mm2 and 0.07 mm2, 0.03 mm2 and 0.05 mm2, 0.07 mm2 and 1.0 mm2, 0.07 mm2 and 0.9 mm2, 0.07 mm2 and 0.8 mm2, 0.07 mm2 and 0.7 mm2, 0.07 mm2 and 0.6 mm2, 0.07 mm2 and 0.5 mm2, 0.07 mm2 and 0.4 mm2, 0.07 mm2 and 0.3 mm2, 0.07 mm2 and 0.2 mm2, 0.07 mm2 and 0.1 mm2, 0.1 mm2 and 1.0 mm2, 0.1 mm2 and 0.9 mm2, 0.1 mm2 and 0.8 mm2, 0.1 mm2 and 0.7 mm2, 0.1 mm2 and 0.6 mm2, 0.1 mm2 and 0.5 mm2, 0.1 mm2 and 0.4 mm2, 0.1 mm2 and 0.3 mm2, 0.1 mm2 and 0.2 mm2, 0.3 mm2 and 1.0 mm2, 0.3 mm2 and 0.9 mm2, 0.3 mm2 and 0.8 mm2, 0.3 mm2 and 0.7 mm2, 0.3 mm2 and 0.6 mm2, 0.3 mm2 and 0.5 mm2, 0.3 mm2 and 0.4 mm2, 0.5 mm2 and 1.0 mm2, 0.5 mm2 and 0.9 mm2, 0.5 mm2 and 0.8 mm2, 0.5 mm2 and 0.7 mm2, 0.5 mm2 and 0.6 mm2, 0.7 mm2 and 1.0 mm2, 0.7 mm2 and 0.9 mm2, or 0.7 mm2 and 0.8 mm2). When viewed from the top of the skin (i.e., along the z-direction, as shown in
Any beneficial areal fraction of the skin region can be removed, such as an areal fraction of less than about 70% (e.g., less than about 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 10%, or 5%) or such as between about 5% and 80% (e.g., between about 5% and 10%, 5% and 10%, 5% and 20%, 5% and 25%, 5% and 30%, 5% and 35%, 5% and 40%, 5% and 45%, 5% and 50%, 5% and 55%, 5% and 60%, 5% and 65%, 5% and 70%, 5% and 75%, 10% and 10%, 10% and 20%, 10% and 25%, 10% and 30%, 10% and 35%, 10% and 40%, 10% and 45%, 10% and 50%, 10% and 55%, 10% and 60%, 10% and 65%, 10% and 70%, 10% and 75%, 10% and 80%, 15% and 20%, 15% and 25%, 15% and 30%, 15% and 35%, 15% and 40%, 15% and 45%, 15% and 50%, 15% and 55%, 15% and 60%, 15% and 65%, 15% and 70%, 15% and 75%, 15% and 80%, 20% and 25%, 20% and 30%, 20% and 35%, 20% and 40%, 20% and 45%, 20% and 50%, 20% and 55%, 20% and 60%, 20% and 65%, 20% and 70%, 20% and 75%, or 20% and 80%).
Furthermore, the plurality of tissue portions can be incised or excised in any beneficial pattern within the skin region. Exemplary patterns within the skin region include tile patterns or fractal-like shapes, where the array of hollow tubes can be arranged, e.g., in a base, to effectuate such a pattern. For example, a higher density and/or smaller spacing of tissue portions (e.g., slits and/or holes) can be incised or excised in the skin in center of the pattern or in thicker portions of the skin. In another example, the pattern within the skin can be random, staggered rows, parallel rows, a circular pattern, a spiral pattern, a square or rectangular pattern, a triangular pattern, a hexagonal pattern, a radial distribution, or a combination of one or more such patterns of the incised or excised tissue portions. The pattern can arise from modifications to the average length, depth, or width of an incised or excised tissue portion, as well as the density, orientation, and spacing between such incisions and/or excisions (e.g., by using an apparatus having one or more blades or tubes with differing lengths, widths, or geometries that are arranged in a particular density or spacing pattern). Such patterns can be optimized to promote unidirectional, non-directional, or multidirectional contraction or expansion of skin (e.g., in the x-direction, y-direction, x-direction, x-y plane, y-z plane, x-z plane, and/or xyz-plane), such as by modifying the average length, depth, width, density, orientation, and/or spacing between incisions and/or excisions.
Any useful portion of the skin can be incised or excised. Such tissue portions can include epidermal tissue, dermal tissue, and/or cells or tissue proximal to the dermal/fatty layer boundary (e.g., stem cells). In particular embodiments, the incised or excised tissue portions forms a hole in the skin region, where the depth of the hole is more than about 1.0 mm and results in a tissue portion having a length that is more than about 1.0 mm (e.g., about 1.0 mm, 1.5 mm, 2.0 mm. 2.5 mm, 3.0 mm, or 3.5 mm). In particular embodiments, the incised or excised tissue portions forms a slit in the skin region, where the depth of the slit is more than about 1.0 mm and results in a tissue portion having a length that is more than about 1.0 mm (e.g., about 1.0 mm, 1.5 mm, 2.0 mm. 2.5 mm, 3.0 mm, or 3.5 mm). In some embodiments, the tissue portion has a length that corresponds to a typical total depth of the skin layer (e.g., epidermal and dermal layers). Based on the part of the body, the total depth of the epidermal and dermal layers can vary. In some embodiments, the depth of the epidermal layer is between about 0.8 mm to 1.4 mm, and/or the depth of the dermal layer is between about 0.3 mm to 4.0 mm. In other embodiments, the total depth of the skin layer (e.g., epidermal and dermal layers) is between about 1.0 mm and 5.5 mm, thereby resulting in a tissue portion having a length between about 1.0 mm and 5.5 mm (e.g., between about 1.0 mm and 1.5 mm, 1.0 mm and 2.0 mm, 1.0 mm and 2.5 mm, 1.0 mm and 3.0 mm, 1.0 mm and 3.5 mm, 1.0 mm and 4.0 mm, 1.0 mm and 4.5 mm, 1.0 mm and 5.0 mm, 1.5 mm and 2.0 mm, 1.5 mm and 2.5 mm, 1.5 mm and 3.0 mm, 1.5 mm and 3.5 mm, 1.5 mm and 4.0 mm, 1.5 mm and 4.5 mm, 1.5 mm and 5.0 mm, 1.5 mm and 5.5 mm, 2.0 mm and 2.5 mm, 2.0 mm and 3.0 mm, 2.0 mm and 3.5 mm, 2.0 mm and 4.0 mm, 2.0 mm and 4.5 mm, 2.0 mm and 5.0 mm, 2.0 and 5.5 mm, 2.5 mm and 3.0 mm, 2.5 mm and 3.5 mm, 2.5 mm and 4.0 mm, 2.5 mm and 4.5 mm, 2.5 mm and 5.0 mm, 2.5 mm and 5.5 mm, 3.0 mm and 3.5 mm, 3.0 mm and 4.0 mm, 3.0 mm and 4.5 mm, 3.0 mm and 5.0 mm, 3.0 and 5.5 mm, 3.5 mm and 4.0 mm, 3.5 mm and 4.5 mm, 3.5 mm and 5.0 mm, 3.5 and 5.5 mm, 4.0 mm and 4.5 mm, 4.0 mm and 5.0 mm, 4.0 and 5.5 mm, 4.5 mm and 5.0 mm, 4.5 and 5.5 mm, or 5.0 mm and 5.5 mm). In yet other embodiments, the average total depth of the tissue portion or the skin layer (e.g., epidermal and dermal layers) is about 1.5 mm. In yet other embodiments, the average total depth of the tissue portion or the skin layer (e.g., epidermal and dermal layers) is about 3 mm. In further embodiments, the tissue portion does not include a significant amount of subcutaneous tissue, and any apparatus described herein can be optimized (e.g., with one or more stop arrangements) to control the depth of the incision or excision and/or the length of the incised or excised tissue portions.
Incisions can be performed by any useful procedure or component. For example, a plurality of incised tissue portions can be achieved by use of an ablative laser (e.g., an ablative CO2 laser (about 10600 nm), a superficial fractional CO2 laser, a fractional Er:YAG laser (about 2940 nm), a fractional Er:YSGG laser (about 2790 nm), an Nd-YAG laser (about 1320 nm), a mid-IR fractional photothermolysis laser, or a fractional deep dermal ablation CO2 laser), an ultrasonic apparatus, a non-coherent light source, a radiofrequency source, or a plurality of blades (e.g., substantially parallel blades). In some embodiments, the one or more blades can include connected, adjacent blades to provide narrow, elongated openings (or slits) in the skin region. Exemplary procedures and apparatuses including one or more blades are described in
Excisions can be performed by any useful procedure or component. For example, a plurality of excised tissue portions can be achieved by use of one or more hollow tubes or needles (e.g., where the inner diameter of at least one tube is less than about 0.5 mm, about 0.3 mm, or about 0.2 mm) or one or more solid tubes or needles. Exemplary components for performing excisions include a needle (e.g., a 16 gauge needle having an inner diameter of 1.194 mm; an 18 gauge needle having an inner diameter of 0.838 mm; a 20 gauge needle having an inner diameter of 0.564 mm; a 23 gauge needle having an inner diameter of about 0.337 mm and an outer diameter of about 0.51 mm, thereby resulting in a tissue portion having a dimension (e.g., a width or diameter) of about 0.3 mm; a 25 gauge needle having an inner diameter of about 0.26 mm or a thin-walled 25 gauge needle having an inner diameter of about 0.31 mm and an outer diameter of about 0.51 mm, thereby resulting in a tissue portion having a dimension (e.g., a width or diameter) of about 0.2 mm; a 30 gauge needle having an inner diameter of about 0.159 mm; a 32 gauge needle having an inner diameter of about 0.108 mm; or a 34 gauge needle having an inner diameter of about 0.0826 mm), where such needles can be a hollow biopsy needle or a solid needle; one or more microaugers; or one or more microabraders.
The geometry of the one or more tubes can include at least two points (or prongs) (e.g., at least three, four, five, six, seven, eight, or more points) provided at a distal end of the tube (e.g., to facilitate separation of the tissue portions from the surrounding tissue and/or insertion of the tubes into the skin region), where an angle formed by at least one of the points is about thirty degrees. Exemplary tubes include those having two points (e.g., by grinding in orientations that are 180 degrees apart), three points (e.g., by grinding in orientations that are 120 degrees apart), or four points (e.g., by grinding in orientations that are 90 degrees apart). The points can optionally include a beveled edge (e.g., to further facilitate separation of tissue portions or insertion of tubes).
The points can have any useful geometric configuration. In one example, the tube has a longitudinal axis (i.e., along the length of the tube) and a diameter (i.e., through the cross-section of the tube), as well as a proximal end and the distal end. The distal end can include one or more points, where each point is characterized by angle a (i.e., the angle between each of the opposing lateral sides of the tube that forms the point and the longitudinal axis of the tube). When viewed from the side, the angle formed by a point is characterized by angle 2a. For example, a tip angle of about 30 degrees corresponds to an angle a of about 15 degrees. Furthermore, the angled distal end of the tube can be formed (e.g., by grinding or cutting) at angle a, e.g., to form a second bevel structure at the distal end of a tube, where this second bevel is characterized by angle r3 and is orthogonal to the primary point (or bevel) characterized by angle a. This second bevel can be provided to reduce the size or width of the point. Exemplary angle a and p includes less than about 20 degrees, 15 degrees, 10, degrees, or 5 degrees (e.g., about 15 degrees, 10 degrees, 6 degrees, 5 degrees, or 3 degrees). See, e.g.,
The tubes can optionally include one or more notches within the lumen of the needle (i.e., if the tube is hollow) and/or extensions on the exterior surface of the needle (e.g., at the distal portion of the needle). Such notches and extensions could be useful to promote cutting of tissue surrounding the incised or excised tissue portions. Exemplary needles having such notches and/or extensions include a microauger, as well as any needles provided in
The tubes can optionally include one or more protrusions or barbs within the lumen of the needle (i.e., if the tube is hollow) to promote retention of fat within the needle. In use, an apparatus including such tubes can be inserted into the subcutaneous fat layer and then withdrawn to remove retained fat tissue. See, e.g.,
The components for making incisions and/or excisions (e.g., blades and/or tubes) can be provided in any useful arrangement (e.g., a linear array, a radial array, or any described herein) of one or more components (e.g., two, three, four, five, ten, thirty, fifty, hundred, or more). The spacing between each component (e.g., blade and/or tube) can be of any useful dimension, such as between about 1 mm and 50 mm (e.g., between about 1 mm and 40 mm, 1 mm and 30 mm, 1 mm and 25 mm, 1 mm and 20 mm, 1 mm and 15 mm, 1 mm and 10 mm, 1 mm and 5 mm, 1 mm and 3 mm, 3 mm and 50 mm, 3 mm and 40 mm, 3 mm and 30 mm, 3 mm and 25 mm, 3 mm and 20 mm, 3 mm and 15 mm, 3 mm and 10 mm, 3 mm and 5 mm, 5 mm and 50 mm, 5 mm and 40 mm, 5 mm and 30 mm, 5 mm and 25 mm, 5 mm and 20 mm, 5 mm and 15 mm, 5 mm and 10 mm, 10 mm and 50 mm, 10 mm and 40 mm, 10 mm and 30 mm, 10 mm and 25 mm, 10 mm and 20 mm, 10 mm and 15 mm, 15 mm and 50 mm, 15 mm and 40 mm, 15 mm and 30 mm, 15 mm and 25 mm, 15 mm and 20 mm, 20 mm and 50 mm, 20 mm and 40 mm, 20 mm and 30 mm, 20 mm and 25 mm, 30 mm and 50 mm, 30 mm and 40 mm, or 40 mm and 50 mm). Such arrangements can include one or more tubes and/or blades (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, or more tubes and/or blades, such as between about 2 and 100 tubes and/or blades (e.g., between 2 and 10, 2 and 15, 2 and 20, 2 and 25, 2 and 30, 2 and 35, 2 and 40, 2 and 45, 2 and 50, 2 and 75, 5 and 10, 5 and 15, 5 and 20, 5 and 25, 5 and 30, 5 and 35, 5 and 40, 5 and 45, 5 and 50, 5 and 75, 5 and 100, 10 and 20, 10 and 25, 10 and 30, 10 and 35, 10 and 40, 10 and 45, 10 and 50, 10 and 75, 10 and 100, 15 and 20, 15 and 25, 15 and 30, 15 and 35, 15 and 40, 15 and 45, 15 and 50, 15 and 75, 15 and 100, 20 and 25, 20 and 30, 20 and 35, 20 and 40, 20 and 45, 20 and 50, 20 and 75, 20 and 100, 25 and 30, 25 and 35, 25 and 40, 25 and 45, 25 and 50, 25 and 75, 25 and 100, 30 and 35, 30 and 40, 30 and 45, 30 and 50, 30 and 75, 30 and 100, 35 and 40, 35 and 45, 35 and 50, 35 and 75, 35 and 100, 40 and 45, 40 and 50, 40 and 75, 40 and 100, 50 and 75, or 50 and 100)).
Such arrangements of components can be any of various two-dimensional or three-dimensional patterns along a base holding one or more components for making incisions and/or excisions (e.g., blades and/or tubes). The base can be optionally mounted on a roller apparatus having a cylindrical body with a longitudinal rotational axis, where the one or more blades and/or tubes are arranged on the longitudinal surface of the cylindrical body. In some embodiments, the blade or tube extends as substantially coplanar extensions of the cylindrical body. In use, rotation of the cylindrical body along the skin results in the incision or excision of tissue portions by the blade or tubes. Exemplary roller apparatuses are provided in
Such components for making incisions and/or excisions (e.g., blades and/or tubes) can include one or more stop arrangements (e.g., one or more collars, which can be coupled to the blade to allow for adjustment along the long axis of the blade or which can be coupled to the outer portion of the tube and be adjusted along the long axis of the tube to control the depth of incision or excision in the biological tissue); one or more sleeves around a portion of a blade and/or a tube, such that the sleeve is slidably translatable along the longitudinal axis of the tube or blade (e.g., to incise or excise tissue portions below the surface of the skin region); a vibrating arrangement (e.g., a piezoelectric element, a solenoid, a pneumatic element, or a hydraulic element) that mechanically couples to at least one blade or hollow tube (e.g., to promote insertion of one or more blades or tubes into the skin region, such as by providing an amplitude of vibration in the range of about 50-500 pm (e.g., between about 100-200 pm) or by providing a frequency of the induced vibrations to be between about 10 Hz and about 10 kHz (e.g., between about 500 Hz and about 2 kHz, or even about 1 kHz)); a suction or pressure system (e.g., by squeezing a flexible bulb or deformable membrane attached thereto or by opening a valve leading from a source of elevated pressure, such as a small pump) to stabilize the surrounding skin region prior to incision or excision and/or to facilitate removal of the skin portions from the tube; a pin within the lumen to the tube to facilitate removal of the skin portions from the tube; one or more actuators for positioning, translating, and/or rotating the one or more blades and/or tubes relative to the skin portion or relative to the optional one or more pins; a housing or frame to stabilize the surrounding skin region prior to incision or excision; one or more actuators for positioning and/or translating the one or more pins relative to the skin portion or relative to one or more tubes; one or more sensors (e.g., force sensors, optical sensors, laser fibers, photodetectors, and/or position sensors) in communication with one or more tubes, blades, pins, actuators, valves, or pressure systems to detect the position of the tubes or pins, the presence of a tissue portion in the tube, the position of the apparatus relative to the treated skin portion; a reciprocating arrangement attached to a base or a substrate having one or more attached blades or tubes (e.g., a motor or actuator configured to repeatedly insert and/or withdrawn one or more blades or tubes); a fluid system coupled to the blades and/or tubes to facilitate removal of incised or excised tissue portions or to irrigate the skin portion, e.g., with saline or a phosphate buffered solution; a heat source (e.g., a resistive heater or current) in communication with the blade and/or tube to promote cauterization or ablation of tissue portions; an optical element (e.g., a lens, a prism, a reflector, etc.) to facilitate viewing of the skin portion beneath the apparatus, tube, or blade; and/or an abrading element optionally mounted on a rotating shaft (e.g., to promote dermabrasion).
Exemplary blades, tubes, pins, apparatuses, and methods are provided in
The tubes, blades, pins, and apparatuses can be formed from any useful material and optionally coated or chemically treated to promote incision or excision of a tissue portion and/or to increase precision or effectiveness for treating the skin region. Exemplary materials include metal (e.g., a stainless steel tube, 304 stainless steel, a surgical stainless steel), a biopsy needle, an epoxy, a glass, a polymer, a plastic, a resin, another structurally rigid material, or a similar structure. Exemplary coatings include a lubricant, a low-friction material (e.g., Teflon™), a chromium coating (e.g., ME-92™, such as to increase material strength), a plastic, a polymer (e.g., nylon or polyethylene), a polished metal alloy, or the like.
In particular embodiments, an apparatus for treating skin includes at least one hollow tube including at least two points provided at a distal end thereof and an optional stop arrangement coupled to the outer portion of the tube (e.g., to control and/or limit a distance to which the one tube is inserted into a biological tissue), where the angle formed by at least one of the points is about thirty degrees, where the inner diameter of at least one tube is less than about 1 mm, and where at least one section of the hollow tube is structured to be inserted into a biological tissue to incise or excise at least one tissue therefrom when the tube is withdrawn from the tissue. In other embodiments, the apparatus further includes a pin provided at least partially within the central lumen of a tube, where the pin is controllably translatable in a direction along a longitudinal axis of the one tube and the pin is configured to facilitate removal of at least one tissue portion from the tube. In another embodiment, the apparatus for treating skin includes a plurality of cutting arrangements (e.g., blades) structured to form a plurality of spaced-apart micro-slits (e.g., openings) in tissue, where each of the micro-slits has a length of extension along a surface of the tissue that is less than about 2 mm. In other embodiments, the apparatus includes at least one hollow tube (e.g., needle) configured to be at least partially inserted into a biological tissue; at least one opening provided on a wall of the hollow tube; at least one cutting edge protruding from the wall of the hollow tube proximal to the at least one opening; and a sleeve provided around at least a portion of the tube and configured to be translatable along a longitudinal axis of the tube, where a distance from the longitudinal axis of the tube to an outer edge of the sleeve is at least as large as a distance from the longitudinal axis of the tube to an outer portion of the cutting edge. In yet other embodiments, the apparatus includes a substrate; a plurality of hollow tubes (e.g., needles) affixed to the substrate and configured to be at least partially inserted into a biological tissue; at least one opening provided on or in a wall of each of the hollow tubes; at least one cutting edge protruding from the wall of each of the hollow tubes proximal to the at least one opening; and a sleeve provided around at least a portion of each of the tubes, where each tube is configured to be translatable along a longitudinal axis of a corresponding sleeve, and where a distance from the longitudinal axis of each tube to an outer edge of each corresponding sleeve is at least as large as a distance from the longitudinal axis of the tube to an outer portion of the cutting edge of the tube.
The procedures herein can include one or more optional processes that promote effective incision or excision of tissue portions or that benefit healing. Such optional processes include cooling, freezing, or partially freezing the skin portion prior to skin incision or excision (e.g., by applying a cryospray or by contacting a surface of a skin region with a cooled object for an appropriate duration), where such cooling and/or freezing can, e.g., increase mechanical stability of the tissue portions; treatment with red or near-infrared light of the skin portion to further promote healing of the tissue; and/or treatment with an optical energy source, such as any described herein (e.g., an ablative laser).
Exemplary procedures, methods, and apparatuses are provided in U.S. Pub. Nos. 2012/0041430, 2011/0313429, 2011/0251602, 2012/0226214, 2012/0226306 and 2012/0226214; International Pub. Nos. WO 2012/103492, WO 2012/103483, WO 2012/103488, WO 2013/013199, WO 2013/013196, and WO 2012/119131; Fernandes et al., “Micro-Mechanical Fractional Skin Rejuvenation,” Plastic &Reconstructive Surgery 130(5S-1):28 (2012); and Fernandes et al., “Micro-Mechanical Fractional Skin Rejuvenation,” Plastic & Reconstructive Surgery 131(2):216-223 (2013), where each is hereby incorporated by reference in its entirety.
A skin region can be treated by any useful method prior to affixing a dressing. For example, this method can include forming a plurality of small holes is in the skin through the dermal and epidermal layer. Generally, the dimension of the holes is in the range of 50-500 μm in diameter. Without wishing to be limited by theory, it is envisioned that up to 40% of the treated skin surface can be removed and that the amount of removed skin determines the extent of the tightening effect. The holes can be formed surgically, for example, by using a hollow coring needle (e.g., any described herein). Alternative forms of energy, e.g., such as laser, non-coherent light, radio-frequency, or ultrasound, can also be used to form the holes. The holes can be circular or have any other preferred shape (e.g., an elongated shape). After the formation of such holes, the methods and devices (e.g., dressings) described herein (e.g., in the following Examples) can be employed to reduce skin surface and/or tighten skin.
After treating the skin to form a plurality of holes in a skin portion, a tunable dressing can be used to compress the skin. In one embodiment, the dressing comprises an adhesive layer that is in contact with the skin and a tension-regulation layer (a regulatable layer) that is affixed to the adhesive layer. The tension-regulation layer allows adjustment of the dimension of the dressing in the plane of the dressing (e.g., parallel to the skin in the x-direction in
In particular embodiments, the dressing is applied on a treated skin area in a tensionless state. At that stage, the dressing does not apply any lateral force on the small wounds or holes. The regulatable layer is then activated, altering the geometry of the dressing. The dressing shrinks and applies a lateral force closing the small wounds.
The tension-regulation layer can any useful material, e.g., a stimulus-responsive polymer, such as a shape-memory material or any described herein. Stimulus-responsive polymers are materials that can change properties with variation of their environment. For example, geometrical and mechanical properties of certain types of polymers can change in response to changes in temperature, pH, light, moisture, magnetic field. Shape-memory polymers are stimulus-responsive polymers and exhibit similar behaviors as shape-memory alloys; their dimension and elastic properties respond to changes in temperature. Fabrics constituted of shape-memory polymers can be manufactured by knitting and weaving of shape-memory polymer fibers. Exemplary fabrics and polymers are described herein, as well as in Hu et al., “A review of stimuli-responsive polymers for smart textile applications,” Smart Mater. Struct. 21: article 053001 (2012), which is hereby incorporate by reference. In particular embodiments, the regulatable layer includes a woven article having a shape-memory polymer (SMP), which has a first shape (i.e., before exposure to temperature above the activation threshold) and a second shape (i.e., after exposure to temperature above the activation threshold), and contraction occurs upon exposure to a temperature greater than glass transition temperature of the SMP. Increasing the temperature of the material above a pre-determined threshold above body temperature, for example by using a blowgun, can shorten the fibers irreversibly (i.e., by decreasing the temperature below the threshold does not have any impact on the fibers length), therefore contracting the dressing. The SMP composition can be optimized to have a particular temperature threshold and response to the change in temperature.
Shape-memory materials, e.g., SM Ps, can be programmed with another low temperature threshold below room temperature that reverts dimensional changes observed after exposure to temperature above the high temperature threshold. This mechanism allows the user to expand the dressing, for example, if the dressing is too tight after high-temperature contraction. The dressing temperature can be altered for example by using a cooling blowgun or by applying a cold surface on the dressing.
The dressing can include any useful material in the regulatable layer. In one embodiment, the tension-regulation layer can integrate a shape-memory alloy (SMA) material in any useful form, e.g., in the form of wires. The SMA can be geometrically arranged, and its mechanical properties can be optimized to respond to particular changes in temperature. In one non-limiting embodiment, a network of SMA wires is arranged in the regulatable layer, e.g., tension-regulation layer 105, e.g., a grid of SMA wires 201, as shown in
Similar to the dressing in the above-described example, elevation of temperature can irreversibly alter the wound-dressing geometry, and the SMA can be programmed with another low temperature threshold below room temperature that reverts dimensional changes observed after exposure to temperature above the high temperature threshold. In this manner, a user can expand the dressing, for example, if the dressing is too tight after high-temperature contraction.
The entire dressing or a portion of the dressing (e.g., a limited surface of the dressing) can be activated or tuned, such as by heating the dressing locally when a thermal-responsive material (e.g., a shape-memory alloy) is used. The level of activation of the dressing can also be varied by the level of heating, e.g., heating the entire thermally-responsive material or the entire grid including such a material will result in full activation, while partial heating will result in partial activation. In other words, the level of skin tightening can be controlled gradually (e.g., in intensity) and spatially (e.g., in the x-, y-, z-, xy-, xz-, yz-, or xyz-direction).
Having described dressing including an SMP and/or SMA in the above examples, the same concept can be applied with one or more other stimuli, for example, moisture, solvent, pH, light, electric field, and/or magnetic field, by using any useful material (e.g., as described herein).
Having described exemplary dressing including fibers or grids of an SMP and/or SMA, other form factors can be envisioned for the stimulus-responsive material. Exemplary forms of such materials include a film, a membrane (e.g., as in temperature shrink wrap), or an actuator having more complex geometries.
The present invention also includes methods of tightening skin in a preferred direction. It might be advantageous to tighten the skin in a pre-determined direction, for example, in the case of a breast lift or an eyebrow lift. In one particular example, it is advantageous to close ablations following Langer lines.
The mechanism proposed in Method 1 (Examples 2 and 3) would result in non-directional tightening. The dressing concept can easily be modified to provide unidirectional tightening, for example, by aligning the shape-memory polymer fibers along the preferred direction of tightening. Activation of the fibers (i.e., fibers shortening) results in a compression of the dressing along the axis of the fibers. The same concept can be applied to shape-memory alloy wires or other actuators having a preferred direction of contraction.
An alternative embodiment includes a dressing that expands in a direction perpendicular to the direction of tightening. In
As shown in
When using dressing to compress the skin and close the holes, it might be advantageous to apply an optimal compression level. Tissue can be compressed by a wound dressing as described above in Method 1. The state of the tissue provides feedback about the optimal compression level. For example, it might be advantageous to close the holes but control or regulate the extent of tissue pleating. Tissue pleating might affect the wound healing process.
The present invention also includes optimizing the dimension of the incised or excised tissue portions to promote wound healing. It might be advantageous to generate small holes that are not circular to promote wound healing. For example, pre-stretching the skin before treatment with a circular coring needle generates an elliptical hole in a non-stretched skin. The long axis of the ellipse is perpendicular to the pre-stretching direction. An elliptical hole can generate skin tightening preferentially in the direction of the short axis of the ellipse. Accordingly, the devices of the invention (e.g., a. dressing, as described herein) can be affixed to a skin portion including one or more elliptical holes or one or more incised or excised tissue portions having one or more elliptical geometries.
All publications, patent applications, and patents mentioned in this specification are herein incorporated by reference.
Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific desired embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the fields of medicine, pharmacology, or related fields are intended to be within the scope of the invention.
This application is a Continuation Application of U.S. patent application Ser. No. 16/707,122, filed on Dec. 9, 2019, which is a Divisional Application of U.S. patent application Ser. No. 14/764,866, filed on Jul. 30, 2015, now U.S. Pat. No. 10,543,127, issued on Jan. 28, 2020, which is a U.S. National Phase Application under 35 U.S.C. § 371 of International Patent Application No. PCT/US2014/016483, filed on Feb. 14, 2014, which claims benefit of U.S. Provisional Application No. 61/766,937, filed Feb. 20, 2013, the contents of each of which are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2426535 | Turkel | Aug 1947 | A |
| 2496111 | Turkel | Jan 1950 | A |
| 2881763 | Robbins | Apr 1959 | A |
| 3001522 | Silverman | Sep 1961 | A |
| 3086530 | Groom | Apr 1963 | A |
| 3214869 | Stryker | Nov 1965 | A |
| 3598108 | Jamshidi et al. | Aug 1971 | A |
| 3640279 | Brown et al. | Feb 1972 | A |
| 3683892 | Harris | Aug 1972 | A |
| 3788320 | Dye | Jan 1974 | A |
| 3867942 | Bellantoni et al. | Feb 1975 | A |
| 3929123 | Jamshidi | Dec 1975 | A |
| 4108096 | Ciecior | Aug 1978 | A |
| 4159659 | Nightingale | Jul 1979 | A |
| 4167179 | Kirsch | Sep 1979 | A |
| 4403617 | Tretinyak | Sep 1983 | A |
| 4458678 | Yannas et al. | Jul 1984 | A |
| 4476864 | Tezel | Oct 1984 | A |
| 4604346 | Bell et al. | Aug 1986 | A |
| 4640296 | Schnepp-Pesch et al. | Feb 1987 | A |
| 4649918 | Pegg et al. | Mar 1987 | A |
| D297375 | Liu | Aug 1988 | S |
| 4815462 | Clark | Mar 1989 | A |
| 4865026 | Barrett | Sep 1989 | A |
| 4903709 | Skinner | Feb 1990 | A |
| 4930997 | Bennett | Jun 1990 | A |
| 5052999 | Klein | Oct 1991 | A |
| D323034 | Reinstein | Jan 1992 | S |
| 5152763 | Johnson | Oct 1992 | A |
| D338070 | Lam | Aug 1993 | S |
| 5242453 | Gubich | Sep 1993 | A |
| D342138 | Wollman et al. | Dec 1993 | S |
| 5269316 | Spitalny | Dec 1993 | A |
| 5306490 | Barley, Jr. | Apr 1994 | A |
| 5324305 | Kanner | Jun 1994 | A |
| 5331972 | Wadhwani et al. | Jul 1994 | A |
| 5415182 | Chin et al. | May 1995 | A |
| 5417683 | Shiao | May 1995 | A |
| 5419761 | Narayanan et al. | May 1995 | A |
| 5439475 | Bennett | Aug 1995 | A |
| 5458112 | Weaver | Oct 1995 | A |
| D377404 | Izumi | Jan 1997 | S |
| 5593381 | Tannenbaum et al. | Jan 1997 | A |
| 5611810 | Amold et al. | Mar 1997 | A |
| 5615690 | Giurtino et al. | Apr 1997 | A |
| 5639654 | Bernard et al. | Jun 1997 | A |
| 5643308 | Markman | Jul 1997 | A |
| D388543 | Eguchi et al. | Dec 1997 | S |
| 5713375 | McAllister | Feb 1998 | A |
| 5749895 | Sawyer et al. | May 1998 | A |
| 5792169 | Markman | Aug 1998 | A |
| 5810857 | MacKool | Sep 1998 | A |
| 5827297 | Boudjema | Oct 1998 | A |
| 5868744 | Willmen | Feb 1999 | A |
| 5871495 | Mueller | Feb 1999 | A |
| 5879326 | Godshall et al. | Mar 1999 | A |
| 5885211 | Eppstein et al. | Mar 1999 | A |
| 5885226 | Rubinstein et al. | Mar 1999 | A |
| 5902319 | Daley | May 1999 | A |
| 5922000 | Chodorow | Jul 1999 | A |
| 5925002 | Wollman | Jul 1999 | A |
| 5928162 | Giurtino et al. | Jul 1999 | A |
| 5931855 | Buncke | Aug 1999 | A |
| 5989273 | Arnold | Nov 1999 | A |
| 6022324 | Skinner | Feb 2000 | A |
| 6027512 | Bridges | Feb 2000 | A |
| D425241 | Nishizawa et al. | May 2000 | S |
| 6059807 | Boudjema | May 2000 | A |
| 6063094 | Rosenberg | May 2000 | A |
| 6178346 | Amundson et al. | Jan 2001 | B1 |
| 6197039 | Ashraf | Mar 2001 | B1 |
| 6211598 | Dhuler et al. | Apr 2001 | B1 |
| 6241687 | Voegele et al. | Jun 2001 | B1 |
| 6241739 | Waldron | Jun 2001 | B1 |
| 6251097 | Kline et al. | Jun 2001 | B1 |
| 6264618 | Landi et al. | Jul 2001 | B1 |
| 6342213 | Barley et al. | Jan 2002 | B1 |
| D457265 | Gebhard | May 2002 | S |
| D458710 | Altamore et al. | Jun 2002 | S |
| 6419641 | Mark et al. | Jul 2002 | B1 |
| 6432098 | Kline et al. | Aug 2002 | B1 |
| 6440086 | Hohenberg | Aug 2002 | B1 |
| 6461369 | Kim | Oct 2002 | B1 |
| 6494844 | Van Bladel et al. | Dec 2002 | B1 |
| 6537242 | Palmer | Mar 2003 | B1 |
| 6537264 | Cormier et al. | Mar 2003 | B1 |
| 6544239 | Kinsey et al. | Apr 2003 | B2 |
| 6562037 | Paton et al. | May 2003 | B2 |
| 6592530 | Farhadi | Jul 2003 | B1 |
| 6626890 | Nguyen et al. | Sep 2003 | B2 |
| 6669618 | Reising et al. | Dec 2003 | B2 |
| 6669694 | Shadduck | Dec 2003 | B2 |
| 6689072 | Kaplan et al. | Feb 2004 | B2 |
| 6730098 | Chang | May 2004 | B2 |
| 6733496 | Sharkey et al. | May 2004 | B2 |
| 6733498 | Paton et al. | May 2004 | B2 |
| 6758842 | Irion et al. | Jul 2004 | B2 |
| 6795728 | Chornenky et al. | Sep 2004 | B2 |
| D500391 | Nielsen et al. | Dec 2004 | S |
| 6875613 | Shartle et al. | Apr 2005 | B2 |
| 6881203 | Delmore et al. | Apr 2005 | B2 |
| 6887250 | Dority et al. | May 2005 | B1 |
| 6893388 | Reising et al. | May 2005 | B2 |
| 6908453 | Fleming et al. | Jun 2005 | B2 |
| 6916328 | Brett | Jul 2005 | B2 |
| 6936039 | Kline et al. | Aug 2005 | B2 |
| D509301 | Talbot et al. | Sep 2005 | S |
| 6945952 | Kwon | Sep 2005 | B2 |
| 6997923 | Anderson et al. | Feb 2006 | B2 |
| 7001355 | Nunomura et al. | Feb 2006 | B2 |
| 7044938 | La Bianco et al. | May 2006 | B2 |
| 7073510 | Redmond et al. | Jul 2006 | B2 |
| 7101359 | Kline et al. | Sep 2006 | B2 |
| 7108681 | Gartstein et al. | Sep 2006 | B2 |
| 7131951 | Angel | Nov 2006 | B2 |
| 7156856 | Feller | Jan 2007 | B2 |
| 7160326 | Ball | Jan 2007 | B2 |
| D538430 | Ohta | Mar 2007 | S |
| 7198641 | Barrows | Apr 2007 | B2 |
| 7226457 | Carson et al. | Jun 2007 | B2 |
| 7270641 | Glucksman et al. | Sep 2007 | B2 |
| 7343920 | Toby et al. | Mar 2008 | B2 |
| 7350983 | Saitoh et al. | Apr 2008 | B2 |
| 7364565 | Freeman | Apr 2008 | B2 |
| 7372608 | Fujimori | May 2008 | B2 |
| 7384417 | Cucin | Jun 2008 | B2 |
| 7407468 | Reising et al. | Aug 2008 | B2 |
| 7419472 | Hibner et al. | Sep 2008 | B2 |
| 7429265 | O'Malley et al. | Sep 2008 | B2 |
| 7473232 | Teague | Jan 2009 | B2 |
| 7513904 | Sulamanidze et al. | Apr 2009 | B2 |
| 7549972 | Luloh et al. | Jun 2009 | B2 |
| 7608049 | Goldenberg | Oct 2009 | B2 |
| 7618429 | Mulholland | Nov 2009 | B2 |
| 7618809 | Gebing | Nov 2009 | B2 |
| 7621934 | Bodduluri et al. | Nov 2009 | B2 |
| 7651507 | Mishra et al. | Jan 2010 | B2 |
| 7658728 | Yuzhakov | Feb 2010 | B2 |
| 7658742 | Karasiuk | Feb 2010 | B2 |
| 7683234 | Gurtner et al. | Mar 2010 | B2 |
| 7704274 | Boyle et al. | Apr 2010 | B2 |
| 7708746 | Eriksson et al. | May 2010 | B2 |
| 7717274 | Kao et al. | May 2010 | B2 |
| 7722549 | Nakao | May 2010 | B2 |
| 7722550 | McClellan | May 2010 | B2 |
| 7753888 | Mukerjee et al. | Jul 2010 | B2 |
| 7776025 | Bobo, Jr. | Aug 2010 | B2 |
| 7785333 | Miyamoto et al. | Aug 2010 | B2 |
| 7785339 | Cohen | Aug 2010 | B2 |
| 7820875 | Roe et al. | Oct 2010 | B2 |
| 7834232 | Rastegar et al. | Nov 2010 | B2 |
| 7841990 | Mark et al. | Nov 2010 | B2 |
| 7850656 | McKay et al. | Dec 2010 | B2 |
| 7926401 | Mishra et al. | Apr 2011 | B2 |
| 7962192 | Bodduluri et al. | Jun 2011 | B2 |
| 7967816 | Ocel et al. | Jun 2011 | B2 |
| 8043614 | Ahlfors | Oct 2011 | B2 |
| 8128639 | Tippett | Mar 2012 | B2 |
| 8133237 | Oostman, Jr. et al. | Mar 2012 | B2 |
| 8150505 | Herndon | Apr 2012 | B2 |
| 8163252 | Booker et al. | Apr 2012 | B2 |
| 8209006 | Smith et al. | Jun 2012 | B2 |
| 8216224 | Morris et al. | Jul 2012 | B2 |
| 8226663 | Remsburg et al. | Jul 2012 | B2 |
| 8226664 | Drews et al. | Jul 2012 | B2 |
| 8246611 | Paithankar et al. | Aug 2012 | B2 |
| 8328738 | Frankhouser et al. | Dec 2012 | B2 |
| 8349554 | Bahrami et al. | Jan 2013 | B2 |
| 8353861 | Tobinaga et al. | Jan 2013 | B2 |
| 8357164 | Miklosovic | Jan 2013 | B2 |
| 8376984 | James | Feb 2013 | B2 |
| 8388631 | Oostman, Jr. et al. | Mar 2013 | B2 |
| 8435791 | Galun et al. | May 2013 | B2 |
| 8480592 | Chudzik et al. | Jul 2013 | B2 |
| 8491497 | Houser et al. | Jul 2013 | B2 |
| 8500754 | Hull, Jr. | Aug 2013 | B2 |
| 8512277 | Del Vecchio | Aug 2013 | B2 |
| 8535299 | Giovannoli | Sep 2013 | B2 |
| 8545489 | Giovannoli | Oct 2013 | B2 |
| 8546384 | Utecht et al. | Oct 2013 | B2 |
| 8568382 | Kline et al. | Oct 2013 | B2 |
| 8574253 | Gruber et al. | Nov 2013 | B2 |
| 8592640 | Zepeda et al. | Nov 2013 | B2 |
| 8597204 | Flatland et al. | Dec 2013 | B2 |
| 8656929 | Miller et al. | Feb 2014 | B2 |
| 8663163 | Iwase et al. | Mar 2014 | B2 |
| 8696686 | Drews et al. | Apr 2014 | B2 |
| 8795262 | Pini et al. | Aug 2014 | B2 |
| 8814882 | Oostman, Jr. et al. | Aug 2014 | B2 |
| 8900181 | Knowlton | Dec 2014 | B2 |
| 8936557 | Al-Mohizea | Jan 2015 | B2 |
| 8951266 | Zingaretti et al. | Feb 2015 | B2 |
| 8979912 | Na et al. | Mar 2015 | B2 |
| 8980628 | Qiao et al. | Mar 2015 | B2 |
| 9005158 | Danenberg et al. | Apr 2015 | B2 |
| 9017343 | Westerling, Jr. et al. | Apr 2015 | B2 |
| 9060803 | Anderson et al. | Jun 2015 | B2 |
| 9084465 | Oostman, Jr. et al. | Jul 2015 | B2 |
| 9119945 | Simons et al. | Sep 2015 | B2 |
| 9121561 | Thullier et al. | Sep 2015 | B2 |
| 9198686 | Motai et al. | Dec 2015 | B2 |
| 9216011 | Wiksell | Dec 2015 | B2 |
| 9283029 | Britva et al. | Mar 2016 | B2 |
| 9301497 | Hilpert et al. | Apr 2016 | B2 |
| 9314262 | Harris | Apr 2016 | B2 |
| 9408691 | Oostman et al. | Aug 2016 | B2 |
| 9414815 | Miller et al. | Aug 2016 | B2 |
| 9439673 | Austen | Sep 2016 | B2 |
| 9446189 | Rimsa et al. | Sep 2016 | B2 |
| 9468459 | Hall et al. | Oct 2016 | B2 |
| 9480496 | Cole et al. | Nov 2016 | B2 |
| 9486274 | Clark, III et al. | Nov 2016 | B2 |
| 9498611 | Tokumoto et al. | Nov 2016 | B2 |
| 9517297 | Almohizea | Dec 2016 | B2 |
| 9522269 | Zhu | Dec 2016 | B2 |
| 9561051 | Austen et al. | Feb 2017 | B2 |
| 9682222 | Burton et al. | Jun 2017 | B2 |
| D797286 | Ginggen et al. | Sep 2017 | S |
| 9775645 | Boone, III | Oct 2017 | B2 |
| 9782574 | Simmers | Oct 2017 | B2 |
| 9827006 | Anderson et al. | Nov 2017 | B2 |
| 9895162 | Anderson et al. | Feb 2018 | B2 |
| 9895520 | Burton et al. | Feb 2018 | B2 |
| 9993664 | Aviad et al. | Jun 2018 | B2 |
| 10035008 | Brandwein et al. | Jul 2018 | B2 |
| 10219827 | Knowlton | Mar 2019 | B2 |
| 10232157 | Berry et al. | Mar 2019 | B2 |
| 10238812 | Ignon | Mar 2019 | B2 |
| 10245066 | Austen et al. | Apr 2019 | B2 |
| 10251792 | Levinson et al. | Apr 2019 | B2 |
| 10278677 | Austen et al. | May 2019 | B2 |
| 10315046 | Stoianovici et al. | Jun 2019 | B2 |
| 10327800 | Austen | Jun 2019 | B2 |
| 10517640 | Shiao | Dec 2019 | B2 |
| 10543127 | Levinson et al. | Jan 2020 | B2 |
| 10549079 | Burton et al. | Feb 2020 | B2 |
| 10555754 | Ginggen et al. | Feb 2020 | B2 |
| 10624698 | Anderson et al. | Apr 2020 | B2 |
| 10687842 | Austen et al. | Jun 2020 | B2 |
| 10716591 | Anderson et al. | Jul 2020 | B2 |
| 10736654 | Anderson et al. | Aug 2020 | B2 |
| 10737081 | Jung et al. | Aug 2020 | B2 |
| 10799285 | Mulholland | Oct 2020 | B2 |
| 10953143 | Ginggen et al. | Mar 2021 | B2 |
| 11166743 | Levinson et al. | Nov 2021 | B2 |
| 11534344 | Levinson | Dec 2022 | B2 |
| 20010018572 | Kinsey et al. | Aug 2001 | A1 |
| 20020022854 | Irion et al. | Feb 2002 | A1 |
| 20020022861 | Jacobs et al. | Feb 2002 | A1 |
| 20020045859 | Gartstein et al. | Apr 2002 | A1 |
| 20020055689 | Kaplan et al. | May 2002 | A1 |
| 20020082667 | Shadduck | Jun 2002 | A1 |
| 20020091385 | Paton et al. | Jul 2002 | A1 |
| 20020103500 | Gildenberg | Aug 2002 | A1 |
| 20020120260 | Morris et al. | Aug 2002 | A1 |
| 20020161357 | Anderson et al. | Oct 2002 | A1 |
| 20020169431 | Kline et al. | Nov 2002 | A1 |
| 20020183688 | Lastovich et al. | Dec 2002 | A1 |
| 20020187556 | Shartle et al. | Dec 2002 | A1 |
| 20020188280 | Nguyen et al. | Dec 2002 | A1 |
| 20020188292 | Sharkey et al. | Dec 2002 | A1 |
| 20030023196 | Liguori | Jan 2003 | A1 |
| 20030036770 | Markman | Feb 2003 | A1 |
| 20030045837 | Delmore et al. | Mar 2003 | A1 |
| 20030083607 | Bobo, Jr. | May 2003 | A1 |
| 20030088220 | Molander et al. | May 2003 | A1 |
| 20030119641 | Reising et al. | Jun 2003 | A1 |
| 20030135161 | Fleming et al. | Jul 2003 | A1 |
| 20030144656 | Ocel et al. | Jul 2003 | A1 |
| 20030153960 | Chomenky et al. | Aug 2003 | A1 |
| 20030158521 | Ameri | Aug 2003 | A1 |
| 20030158551 | Paton et al. | Aug 2003 | A1 |
| 20030158566 | Brett | Aug 2003 | A1 |
| 20030163160 | O'Malley et al. | Aug 2003 | A1 |
| 20030181936 | Trautman et al. | Sep 2003 | A1 |
| 20030187462 | Chang | Oct 2003 | A1 |
| 20030195625 | Garcia Castro et al. | Oct 2003 | A1 |
| 20030199811 | Sage et al. | Oct 2003 | A1 |
| 20030212415 | Karasiuk | Nov 2003 | A1 |
| 20030233082 | Kline et al. | Dec 2003 | A1 |
| 20040002723 | Ball | Jan 2004 | A1 |
| 20040010222 | Nunomura et al. | Jan 2004 | A1 |
| 20040010268 | Gabehart | Jan 2004 | A1 |
| 20040015139 | La Bianco et al. | Jan 2004 | A1 |
| 20040019297 | Angel | Jan 2004 | A1 |
| 20040023771 | Reising et al. | Feb 2004 | A1 |
| 20040054410 | Barrows | Mar 2004 | A1 |
| 20040073195 | Cucin | Apr 2004 | A1 |
| 20040087893 | Kwon | May 2004 | A1 |
| 20040087992 | Gartstein et al. | May 2004 | A1 |
| 20040098094 | Boyle et al. | May 2004 | A1 |
| 20040122471 | Toby et al. | Jun 2004 | A1 |
| 20040138680 | Twitchell et al. | Jul 2004 | A1 |
| 20040162566 | Carson et al. | Aug 2004 | A1 |
| 20040167430 | Roshdieh et al. | Aug 2004 | A1 |
| 20040175690 | Mishra et al. | Sep 2004 | A1 |
| 20040176787 | Mishra et al. | Sep 2004 | A1 |
| 20040186421 | Freeman | Sep 2004 | A1 |
| 20040220589 | Feller | Nov 2004 | A1 |
| 20050049582 | Debenedictis et al. | Mar 2005 | A1 |
| 20050052630 | Smith et al. | Mar 2005 | A1 |
| 20050065463 | Tobinaga et al. | Mar 2005 | A1 |
| 20050090765 | Fisher | Apr 2005 | A1 |
| 20050130821 | Reising et al. | Jun 2005 | A1 |
| 20050137525 | Wang et al. | Jun 2005 | A1 |
| 20050165329 | Taylor et al. | Jul 2005 | A1 |
| 20050171480 | Mukerjee et al. | Aug 2005 | A1 |
| 20050171567 | Dehart | Aug 2005 | A1 |
| 20050203575 | Carson et al. | Sep 2005 | A1 |
| 20050209567 | Sibbitt | Sep 2005 | A1 |
| 20050215921 | Hibner et al. | Sep 2005 | A1 |
| 20050215970 | Kline et al. | Sep 2005 | A1 |
| 20050215971 | Roe et al. | Sep 2005 | A1 |
| 20050226856 | Ahlfors | Oct 2005 | A1 |
| 20050234419 | Kline et al. | Oct 2005 | A1 |
| 20050245952 | Feller | Nov 2005 | A1 |
| 20050267506 | Harris | Dec 2005 | A1 |
| 20050274679 | Kao et al. | Dec 2005 | A1 |
| 20050283141 | Giovannoli | Dec 2005 | A1 |
| 20060047234 | Glucksman et al. | Mar 2006 | A1 |
| 20060064031 | Miller | Mar 2006 | A1 |
| 20060100611 | Galun et al. | May 2006 | A1 |
| 20060116605 | Nakao | Jun 2006 | A1 |
| 20060155266 | Manstein et al. | Jul 2006 | A1 |
| 20060161179 | Kachenmeister | Jul 2006 | A1 |
| 20060184153 | Mark et al. | Aug 2006 | A1 |
| 20060193819 | Lu et al. | Aug 2006 | A1 |
| 20060216781 | Gebing | Sep 2006 | A1 |
| 20060259006 | McKay et al. | Nov 2006 | A1 |
| 20060264926 | Kochamba | Nov 2006 | A1 |
| 20060271070 | Eriksson et al. | Nov 2006 | A1 |
| 20060276806 | Martinez Zunino | Dec 2006 | A1 |
| 20070010810 | Kochamba | Jan 2007 | A1 |
| 20070031092 | Saitoh et al. | Feb 2007 | A1 |
| 20070038181 | Melamud et al. | Feb 2007 | A1 |
| 20070038236 | Cohen | Feb 2007 | A1 |
| 20070060888 | Goff et al. | Mar 2007 | A1 |
| 20070066186 | Annen et al. | Mar 2007 | A1 |
| 20070068537 | Giovannoli | Mar 2007 | A1 |
| 20070073217 | James | Mar 2007 | A1 |
| 20070073327 | Giovannoli | Mar 2007 | A1 |
| 20070078359 | Luloh et al. | Apr 2007 | A1 |
| 20070078466 | Bodduluri et al. | Apr 2007 | A1 |
| 20070078473 | Bodduluri et al. | Apr 2007 | A1 |
| 20070106306 | Bodduluri et al. | May 2007 | A1 |
| 20070142722 | Chang | Jun 2007 | A1 |
| 20070142744 | Provencher | Jun 2007 | A1 |
| 20070142885 | Hantash et al. | Jun 2007 | A1 |
| 20070149991 | Mulholland | Jun 2007 | A1 |
| 20070156161 | Weadock et al. | Jul 2007 | A1 |
| 20070161964 | Yuzhakov | Jul 2007 | A1 |
| 20070167958 | Sulamanidze et al. | Jul 2007 | A1 |
| 20070171504 | Fujimori | Jul 2007 | A1 |
| 20070179455 | Geliebter et al. | Aug 2007 | A1 |
| 20070179481 | Frangineas et al. | Aug 2007 | A1 |
| 20070183938 | Booker et al. | Aug 2007 | A1 |
| 20070184032 | Mishra et al. | Aug 2007 | A1 |
| 20070198000 | Miyamoto et al. | Aug 2007 | A1 |
| 20070213634 | Teague | Sep 2007 | A1 |
| 20070239236 | Manstein | Oct 2007 | A1 |
| 20070239260 | Palanker et al. | Oct 2007 | A1 |
| 20070249960 | Williamson, IV | Oct 2007 | A1 |
| 20070270710 | Frass et al. | Nov 2007 | A1 |
| 20070156164 | Cole et al. | Dec 2007 | A1 |
| 20080009802 | Lambino et al. | Jan 2008 | A1 |
| 20080009896 | Shiao | Jan 2008 | A1 |
| 20080009901 | Redmond et al. | Jan 2008 | A1 |
| 20080009923 | Paithankar et al. | Jan 2008 | A1 |
| 20080033334 | Gurtner et al. | Feb 2008 | A1 |
| 20080045858 | Tessitore et al. | Feb 2008 | A1 |
| 20080045861 | Miller et al. | Feb 2008 | A1 |
| 20080051805 | Pinchuk | Feb 2008 | A1 |
| 20080132979 | Gerber | Jun 2008 | A1 |
| 20080146982 | Rastegar et al. | Jun 2008 | A1 |
| 20080177287 | Rassman et al. | Jul 2008 | A1 |
| 20080183167 | Britva et al. | Jul 2008 | A1 |
| 20080208146 | Brandwein et al. | Aug 2008 | A1 |
| 20080221548 | Danenberg et al. | Sep 2008 | A1 |
| 20080234602 | Oostman, Jr. et al. | Sep 2008 | A1 |
| 20080234699 | Oostman, Jr. et al. | Sep 2008 | A1 |
| 20080249553 | Gruber et al. | Oct 2008 | A1 |
| 20080269735 | Vila Echague et al. | Oct 2008 | A1 |
| 20080275378 | Herndon | Nov 2008 | A1 |
| 20080300507 | Figueredo et al. | Dec 2008 | A1 |
| 20080306471 | Altshuler et al. | Dec 2008 | A1 |
| 20080312648 | Peterson | Dec 2008 | A1 |
| 20090030340 | McClellan | Jan 2009 | A1 |
| 20090048557 | Yeshurun et al. | Feb 2009 | A1 |
| 20090076497 | Morris et al. | Mar 2009 | A1 |
| 20090088720 | Oostman, Jr. | Apr 2009 | A1 |
| 20090093864 | Anderson | Apr 2009 | A1 |
| 20090125050 | Dixon | May 2009 | A1 |
| 20090163877 | Christoffersen et al. | Jun 2009 | A1 |
| 20090198189 | Simons et al. | Aug 2009 | A1 |
| 20090198336 | Qiao et al. | Aug 2009 | A1 |
| 20090227895 | Goldenberg | Sep 2009 | A1 |
| 20090240261 | Drews et al. | Sep 2009 | A1 |
| 20090312749 | Pini et al. | Dec 2009 | A1 |
| 20100004558 | Frankhouser et al. | Jan 2010 | A1 |
| 20100023003 | Mulholland | Jan 2010 | A1 |
| 20100030152 | Lee et al. | Feb 2010 | A1 |
| 20100041938 | Stoianovici et al. | Feb 2010 | A1 |
| 20100042014 | Djordjevic et al. | Feb 2010 | A1 |
| 20100057100 | Zeevi | Mar 2010 | A1 |
| 20100082042 | Drews | Apr 2010 | A1 |
| 20100121307 | Lockard et al. | May 2010 | A1 |
| 20100145373 | Alon | Jun 2010 | A1 |
| 20100160822 | Parihar et al. | Jun 2010 | A1 |
| 20100185116 | Al-Mohizea | Jul 2010 | A1 |
| 20100191253 | Oostman, Jr. et al. | Jul 2010 | A1 |
| 20100286618 | Choi | Nov 2010 | A1 |
| 20100330589 | Bahrami et al. | Dec 2010 | A1 |
| 20110009882 | Remsburg et al. | Jan 2011 | A1 |
| 20110028898 | Clark, III et al. | Feb 2011 | A1 |
| 20110046616 | Manstein | Feb 2011 | A1 |
| 20110092844 | Bargo et al. | Apr 2011 | A1 |
| 20110105949 | Wiksell | May 2011 | A1 |
| 20110152716 | Chudzik et al. | Jun 2011 | A1 |
| 20110152738 | Zepeda et al. | Jun 2011 | A1 |
| 20110166520 | Iwase et al. | Jul 2011 | A1 |
| 20110172745 | Na et al. | Jul 2011 | A1 |
| 20110224761 | Manstein | Sep 2011 | A1 |
| 20110245726 | Flatland et al. | Oct 2011 | A1 |
| 20110245834 | Miklosovic | Oct 2011 | A1 |
| 20110251602 | Anderson et al. | Oct 2011 | A1 |
| 20110257588 | Knowlton | Oct 2011 | A1 |
| 20110270274 | Hull, Jr. | Nov 2011 | A1 |
| 20110282238 | Houser et al. | Nov 2011 | A1 |
| 20110288562 | Tippett | Nov 2011 | A1 |
| 20110313345 | Schafer | Dec 2011 | A1 |
| 20110313429 | Anderson et al. | Dec 2011 | A1 |
| 20120010526 | Hilpert et al. | Jan 2012 | A1 |
| 20120010527 | Sundheimer et al. | Jan 2012 | A1 |
| 20120041430 | Anderson et al. | Feb 2012 | A1 |
| 20120065551 | Aviad et al. | Mar 2012 | A1 |
| 20120136387 | Redmond et al. | May 2012 | A1 |
| 20120158100 | Schomacker | Jun 2012 | A1 |
| 20120179189 | Zingaretti et al. | Jul 2012 | A1 |
| 20120209283 | Hui | Aug 2012 | A1 |
| 20120226214 | Gurtner | Sep 2012 | A1 |
| 20120226268 | Liu et al. | Sep 2012 | A1 |
| 20120226306 | Jackson et al. | Sep 2012 | A1 |
| 20120245629 | Gross et al. | Sep 2012 | A1 |
| 20120253333 | Garden et al. | Oct 2012 | A1 |
| 20120259237 | Axelrod | Oct 2012 | A1 |
| 20120265217 | Drews et al. | Oct 2012 | A1 |
| 20120271320 | Hall et al. | Oct 2012 | A1 |
| 20120289985 | Motai et al. | Nov 2012 | A1 |
| 20130006168 | Del Vecchio | Jan 2013 | A1 |
| 20130041397 | Nishimura | Feb 2013 | A1 |
| 20130045171 | Utecht et al. | Feb 2013 | A1 |
| 20130110026 | Jackson et al. | May 2013 | A1 |
| 20130131635 | Rimsa et al. | May 2013 | A1 |
| 20130150826 | Almohizea | Jun 2013 | A1 |
| 20130204238 | Lederman et al. | Aug 2013 | A1 |
| 20140036523 | Thullier et al. | Feb 2014 | A1 |
| 20140039523 | Austen | Feb 2014 | A1 |
| 20140163582 | Austen et al. | Jun 2014 | A1 |
| 20140171827 | Westerling, Jr. et al. | Jun 2014 | A1 |
| 20140200484 | Austen et al. | Jul 2014 | A1 |
| 20140243747 | Tokumoto et al. | Aug 2014 | A1 |
| 20140249547 | Boone, III | Sep 2014 | A1 |
| 20140276205 | Miller et al. | Sep 2014 | A1 |
| 20140276959 | Oostman et al. | Sep 2014 | A1 |
| 20140277055 | Austen, Jr. | Sep 2014 | A1 |
| 20140296741 | Austen | Oct 2014 | A1 |
| 20140296796 | Lim | Oct 2014 | A1 |
| 20140303648 | Knowlton | Oct 2014 | A1 |
| 20140343481 | Ignon | Nov 2014 | A1 |
| 20150032129 | Oostman, Jr. et al. | Jan 2015 | A1 |
| 20150143713 | Cheng | May 2015 | A1 |
| 20150173991 | Anderson et al. | Jun 2015 | A1 |
| 20150216545 | Anderson et al. | Aug 2015 | A1 |
| 20150238214 | Anderson et al. | Aug 2015 | A1 |
| 20150258319 | Simmers | Sep 2015 | A1 |
| 20150320990 | Burton et al. | Nov 2015 | A1 |
| 20150366719 | Levinson et al. | Dec 2015 | A1 |
| 20160082241 | Burton et al. | Mar 2016 | A1 |
| 20160095592 | Levinson et al. | Apr 2016 | A1 |
| 20160121091 | Burton et al. | May 2016 | A1 |
| 20160129198 | Bitar et al. | May 2016 | A1 |
| 20160136406 | Berry et al. | May 2016 | A1 |
| 20160192961 | Ginggen et al. | Jul 2016 | A1 |
| 20160317721 | Ginggen et al. | Nov 2016 | A1 |
| 20160361527 | Jung et al. | Dec 2016 | A1 |
| 20160367280 | Austen | Dec 2016 | A1 |
| 20170105749 | Austen et al. | Apr 2017 | A1 |
| 20170367729 | Ginggen et al. | Dec 2017 | A1 |
| 20180008500 | Anderson et al. | Jan 2018 | A1 |
| 20180021087 | Anderson et al. | Jan 2018 | A1 |
| 20180036029 | Anderson et al. | Feb 2018 | A1 |
| 20180078278 | Levinson et al. | Mar 2018 | A1 |
| 20180140316 | Anderson et al. | May 2018 | A1 |
| 20180185196 | Levinson et al. | Jul 2018 | A1 |
| 20180193054 | Austen | Jul 2018 | A1 |
| 20180206875 | Austen et al. | Jul 2018 | A1 |
| 20190099199 | Levinson et al. | Apr 2019 | A1 |
| 20190231324 | Austen et al. | Aug 2019 | A1 |
| 20190366067 | Ginggen et al. | Dec 2019 | A1 |
| 20200038051 | Austen | Feb 2020 | A1 |
| 20200121354 | Ginggen et al. | Apr 2020 | A1 |
| 20200188184 | Levinson et al. | Jun 2020 | A1 |
| 20200214766 | Anderson et al. | Jul 2020 | A1 |
| 20200246039 | Levinson et al. | Aug 2020 | A1 |
| 20200360039 | Anderson et al. | Nov 2020 | A1 |
| 20200360043 | Anderson et al. | Nov 2020 | A1 |
| 20210059703 | Austen et al. | Mar 2021 | A1 |
| 20210178028 | Ginggen et al. | Jun 2021 | A1 |
| 20210322005 | Levinson et al. | Oct 2021 | A1 |
| 20210401453 | Dimatteo et al. | Dec 2021 | A1 |
| 20220054343 | Anderson et al. | Feb 2022 | A1 |
| 20220125477 | Brik et al. | Apr 2022 | A1 |
| 20230210552 | Ginggen et al. | Jul 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 2012211122 | Jul 2016 | AU |
| 1275215 | Oct 1990 | CA |
| 2361777 | May 2002 | CA |
| 2126570 | Jan 1993 | CN |
| 1115629 | Jan 1996 | CN |
| 201005966 | Jan 2008 | CN |
| 101128156 | Feb 2008 | CN |
| 101208128 | Jun 2008 | CN |
| 101232858 | Jul 2008 | CN |
| 101277657 | Oct 2008 | CN |
| 101312692 | Nov 2008 | CN |
| 101347346 | Jan 2009 | CN |
| 201216811 | Apr 2009 | CN |
| 101563113 | Oct 2009 | CN |
| 101670145 | Mar 2010 | CN |
| 102119006 | Jul 2011 | CN |
| 102143724 | Aug 2011 | CN |
| 102178616 | Sep 2011 | CN |
| 202113484 | Jan 2012 | CN |
| 102958460 | Mar 2013 | CN |
| 103547226 | Jan 2014 | CN |
| 105492064 | Apr 2016 | CN |
| 287651 | Mar 1991 | DE |
| 9211681 | Nov 1992 | DE |
| 202004010659 | Oct 2004 | DE |
| 102007026973 | Dec 2008 | DE |
| 9092 | Oct 2007 | EA |
| 0027974 | May 1981 | EP |
| 1224949 | Jul 2002 | EP |
| 1396230 | Mar 2004 | EP |
| 1618925 | Jan 2006 | EP |
| 2181732 | May 2010 | EP |
| 1278061 | Feb 2011 | EP |
| 2409727 | Jan 2012 | EP |
| 2846221 | Jul 2005 | FR |
| 57163208 | Oct 1982 | JP |
| 10210 | Jan 1998 | JP |
| 200039929 | May 2000 | JP |
| 2001187058 | Jul 2001 | JP |
| 2002505605 | Feb 2002 | JP |
| 2003515424 | May 2003 | JP |
| 2003518975 | Jun 2003 | JP |
| 2003532480 | Nov 2003 | JP |
| 2004503342 | Feb 2004 | JP |
| 2004154296 | Jun 2004 | JP |
| 2005000642 | Jan 2005 | JP |
| 200503276 | Apr 2005 | JP |
| 200587519 | Apr 2005 | JP |
| 200587520 | Apr 2005 | JP |
| 2005103276 | Apr 2005 | JP |
| 2005137454 | Jun 2005 | JP |
| 2006516201 | Jun 2006 | JP |
| 2006517814 | Aug 2006 | JP |
| 200700140 | Apr 2007 | JP |
| 2007229330 | Sep 2007 | JP |
| 2008036393 | Feb 2008 | JP |
| 2008528207 | Jul 2008 | JP |
| 2009502413 | Jan 2009 | JP |
| 2009507773 | Feb 2009 | JP |
| 2009509671 | Mar 2009 | JP |
| 2009172418 | Aug 2009 | JP |
| 2009219858 | Oct 2009 | JP |
| 2009545382 | Dec 2009 | JP |
| 2010000210 | Jan 2010 | JP |
| 4431637 | Mar 2010 | JP |
| 2010515469 | May 2010 | JP |
| 2010524591 | Jul 2010 | JP |
| 2010525887 | Jul 2010 | JP |
| 2010532178 | Oct 2010 | JP |
| 2011516168 | May 2011 | JP |
| 2011516169 | May 2011 | JP |
| 2013094530 | May 2013 | JP |
| 2013526300 | Jun 2013 | JP |
| 2013532557 | Aug 2013 | JP |
| 2014506498 | Mar 2014 | JP |
| 5944925 | Jul 2016 | JP |
| 6406915 | Oct 2018 | JP |
| 20080030553 | Apr 2008 | KR |
| 20080049793 | Jun 2008 | KR |
| 20090039073 | Apr 2009 | KR |
| 20100135863 | Dec 2010 | KR |
| 20100135864 | Dec 2010 | KR |
| 20120001871 | Mar 2012 | KR |
| 1020120135429 | Dec 2012 | KR |
| 101571291 | Nov 2015 | KR |
| 1801391 | Mar 1993 | RU |
| 2119304 | Sep 1998 | RU |
| 11679 | Nov 1999 | RU |
| 28328 | Mar 2003 | RU |
| 50799 | Jan 2006 | RU |
| 68359 | Nov 2006 | RU |
| 2289332 | Dec 2006 | RU |
| 2308873 | Oct 2007 | RU |
| 1426740 | Sep 1988 | SU |
| 402497 | Aug 2000 | TW |
| 200841866 | Nov 2008 | TW |
| 9322971 | Nov 1993 | WO |
| 199528896 | Nov 1995 | WO |
| 9718758 | May 1997 | WO |
| 9826719 | Jun 1998 | WO |
| 9829149 | Jul 1998 | WO |
| 9857587 | Dec 1998 | WO |
| 9921497 | May 1999 | WO |
| 9929243 | Jun 1999 | WO |
| 0064379 | Nov 2000 | WO |
| 0074763 | Dec 2000 | WO |
| 0141651 | Jun 2001 | WO |
| 0149186 | Jul 2001 | WO |
| 0185035 | Nov 2001 | WO |
| 0205890 | Jan 2002 | WO |
| 02096321 | Dec 2002 | WO |
| 2004045671 | Jun 2004 | WO |
| 2014151104 | Jun 2004 | WO |
| 2004107984 | Dec 2004 | WO |
| 2005013830 | Feb 2005 | WO |
| 2005072181 | Aug 2005 | WO |
| 2005109799 | Nov 2005 | WO |
| 2006081556 | Aug 2006 | WO |
| 2006116281 | Nov 2006 | WO |
| 2006118804 | Nov 2006 | WO |
| 2007011788 | Jan 2007 | WO |
| 2007015232 | Feb 2007 | WO |
| 2007015247 | Feb 2007 | WO |
| 2007021905 | Feb 2007 | WO |
| 2007024038 | Mar 2007 | WO |
| 2007025106 | Mar 2007 | WO |
| 2007041267 | Apr 2007 | WO |
| 2007066339 | Jun 2007 | WO |
| 2007080596 | Jul 2007 | WO |
| 2007106170 | Sep 2007 | WO |
| 2008019051 | Feb 2008 | WO |
| 2008033873 | Mar 2008 | WO |
| 2008052189 | May 2008 | WO |
| 2008121920 | Oct 2008 | WO |
| 2008131302 | Oct 2008 | WO |
| 2009040493 | Apr 2009 | WO |
| 2009072108 | Jun 2009 | WO |
| 2009072711 | Jun 2009 | WO |
| 2009099988 | Aug 2009 | WO |
| 2009137288 | Nov 2009 | WO |
| 2009146053 | Dec 2009 | WO |
| 2009146068 | Dec 2009 | WO |
| 2009146072 | Dec 2009 | WO |
| 2010027188 | Mar 2010 | WO |
| 2010080014 | Jul 2010 | WO |
| 2010095456 | Aug 2010 | WO |
| 2010097790 | Sep 2010 | WO |
| 2011006009 | Jan 2011 | WO |
| 2011019859 | Feb 2011 | WO |
| 2011075676 | Jun 2011 | WO |
| 2011104875 | Sep 2011 | WO |
| 2011123218 | Oct 2011 | WO |
| 2011140497 | Nov 2011 | WO |
| 2012052986 | Apr 2012 | WO |
| 2012103483 | Aug 2012 | WO |
| 2012103488 | Aug 2012 | WO |
| 2012103492 | Aug 2012 | WO |
| 2012119131 | Sep 2012 | WO |
| 2012135828 | Oct 2012 | WO |
| 2013013196 | Jan 2013 | WO |
| 2013013199 | Jan 2013 | WO |
| 12013104414 | Jul 2013 | WO |
| 2014008481 | Jan 2014 | WO |
| 20140008470 | Jan 2014 | WO |
| 2014028626 | Feb 2014 | WO |
| 2014089488 | Jun 2014 | WO |
| 2014130359 | Aug 2014 | WO |
| 2014179729 | Nov 2014 | WO |
| 2014193727 | Dec 2014 | WO |
| 2015021434 | Feb 2015 | WO |
| 2015051164 | Apr 2015 | WO |
| 2015095675 | Jun 2015 | WO |
| 2015126926 | Aug 2015 | WO |
| 2016033584 | Mar 2016 | WO |
| 2016033586 | Mar 2016 | WO |
| 2016077759 | May 2016 | WO |
| 2016127091 | Aug 2016 | WO |
| 2017139773 | Aug 2017 | WO |
| 2017172920 | Oct 2017 | WO |
| 2017192723 | Nov 2017 | WO |
| 2018057630 | Mar 2018 | WO |
| 2018057637 | Mar 2018 | WO |
| 2020097244 | May 2020 | WO |
| 2022246185 | Nov 2022 | WO |
| 2023049500 | Mar 2023 | WO |
| Entry |
|---|
| International Search Report and Written Opinion dated Apr. 18, 2023 issued in related International Application No. PCT/US2022/044862. |
| De las Heras Alarcon et al., Stimuli responsive polymers for biomedical applications, Chem Soc Rev. 34(3):276-85 (2005). |
| Dini, et al., Grasping Leather Plies by Bernoulli Grippers, CIRP Annals—Manufacturing Technology, 2009, 58:21-24. |
| Dua et al.; Follicular Unit Extraction Hair Transplant; 2010; J Cutan Aesthet Surg. May-Aug. 2010; 3(2):76-81(Year: 2010). |
| Dujardin, et al., In Vivo Assessment of Skinelectroporation Using Square Wave Pulses, Journal of Controlled Release, 2002, 79:219-227. |
| Dunkin, C. et al., Scarring occurs at a critical depth of skin injury: precise measurement in a graduated dermal scratch in human volunteers, Plast Reconstr Surg, 119(6):1722-32 (2007). |
| European Patent Office, Extended European Search Report, Application No. 12814711.3, dated Feb. 11, 2015. |
| European Patent Office, Supplementary European Search Report, Application No. EP13813955.5, dated Mar. 18, 2016. |
| European Patent Office, Supplementary European Search Report, Application No. 12738813, dated Jun. 12, 2014. |
| European Search Report for European Application No. 12739664.6 dated May 20, 2014. |
| Fabi, Noninvasive skin tightening: focus on new ultrasound techniques, Clinical, Cosmetic and Investigative Dermatology, vol. 8 (Feb. 5, 2015), pp. 47-52. |
| Fernandes, et al., Micro-Mechanical Fractional Skin Rejuvenation, Plastic and Reconstructive Surgery, 2012, 130 5S-1):28. |
| Fernandes, et al., Micro-Mechanical Fractional Skin Rejuvenation, Plastic and Reconstructive Surgery, 2013, 131:216-223. |
| Galaev,‘Smart’ Polymers in Biotechnology and Medicine, Russian Chemical Reviews, 1995, 64(5):471-489. |
| Glogau, Aesthetic and Anatomic Analysis of the Aging Skin, Seminars in Cutaneous Medicine and Surgery, 1996, 15 (3):134-138. |
| Goldberg et al. “Skin Rejuvenation with Non-Invasive Pulsed Electric Fields”, Scientific Reports, vol. 5 (May 12, 2015), p. 1-18. |
| Hale, et al., Optical Constants of Water in the 200-nm to 200-μm Wavelength Region, Applied Optics, 1973, 12 (3):555-563. |
| Han, H. et al., Combined, Minimally Invasive, Thread-based Facelift, Archives of Aesthetic Plastic Surgery, 20 (3):160-164 (2014). |
| Huang, et al., Shape Memory Materials, Materials Today, 2010, 13(7):54-61. |
| Kakasheva-Mazenkovska, et al., Variations of the Histomorphological Characteristics of Human Skin of Different Body Regions in Subjects of Different Age, Contributions/Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences, 2010 32(2):119-128. |
| Konermann, et al., Ultrasonographically Guided Needle Biopsy of Benign and Malignant Soft Tissue and Bone Tumors, Journal of Ultrasound in Medicine, 2000, 19(7):465-471. |
| Lee et al. “Combined Treatment with Botulinum Toxin and 595-nm Pulsed Dye Laser for Traumatic Scarring”, Annals of Dermatology, vol. 27, No. 6 (2015), p. 756-758. |
| Lemperle, G. et al., A Classification of Facial Wrinkles, Plastic and Reconstructive Surgery, 108(6):1735-1750 (2001). |
| Lien, et al., A Novel Gripper for Limp Materials Based on Lateral Coanda Ejectors, CIRP Annals—Manufacturing Technology, 2008, 57:33-36. |
| Majid, Microneedling Therapy in Atrophic Facial Scars: An Objective Assessment, Journal of Cutaneous and Aesthetic Surgery, 2009, 2(1):26-30. |
| Moore, J., et al., Modeling of the Plane Needle Cutting Edge Rake and Inclination Angles for Biopsy, Journal of Manufacturing Science and Engineering, 132:051005-1-051005-8 (2010). |
| Narins, R. et al., Validated Assessment Scales for the Lower Face, Dermatology Surgery, 38:333-342 (2012). |
| Paithankar et al. “Acne Treatment Based on Selective Photothermolysis of Sebaceous Follicles with Topically Delivered Light-Absorbing Gold Microparticles”, Journal of Investigative Dermatology, vol. 135 (Apr. 9, 2015) p. 1727-1734. |
| Pliquett, et al., A Propagating Heat Wave Model of Skin Electroporation, Journal of Theoretical Biology, 2008, 251:195-201. |
| Prausnitz, et al_,Electroporation of Mammalian Skin: A Mechanism to Enhance Transdermal Drug Delivery, Proc. Natl. Acad. Sci., 1993, 90:10504-10508. |
| Salam, G. and Amin, J., The basic Z-plasty, Am Fam Physician, 67(11):2329-32 (2003). |
| Spravochik operatsionnoy I perevyazochnoy sestrie, M., «Meditsina», 1985, p. 31. |
| Spravochik Opertsionnoy I Perevyazochnoy Sestrie, M., <&ly;Meditsina>>, 1985, p. 31. |
| Wikipedia; Subcutaneous tissue; https://en.wi?pedia.org/wiki/Subcutaneous-tissue; originally accessed Oct. 18, 2017; accessed again on Jun. 1, 2022. |
| Wong et al. “Hypopigmentation Induced by Frequent Low-Fluence, Large-Spot-Size QS Nd:YAG Laser Treatments”, Annals of Dermatology, vol. 27, No. 6, (2015), p. 751-755. |
| Zhu, J. et al., The Efficacy and Safety of Fractional CO2 Laser Combined with Topical Type A Botulin um Toxin for Facial Rejuvenation: A Randomized Controlled Split-Face Study, BioMed Research International, 7 pages (2016). |
| Australian Office Action dated Jan. 5, 2018 issued in corresponding Australian Application No. 2014219240. |
| Canadian Office Action dated Apr. 20, 2021 issued in corresponding Canadian Application No. 2900505. |
| Canadian Office Action dated Mar. 6, 2020 issued in corresponding Canadian Application No. 2900505. |
| Extended European Search Report dated Oct. 10, 2016 issued in corresponding European Application No. 14754094.2. |
| Israel Office Action dated Jan. 31, 2021 issued in corresponding Israel Application No. 240251, with English summary. |
| Summary of Brazilian Office Action dated Aug. 1, 2021 issued in corresponding Brazilian Application No. 112015019440-0. |
| “Methods and Devices for Skin Tightening” Specification, Drawings and Prosecution History of U.S. Appl. No. 16/707,122, filed Dec. 9, 2019, now U.S. Pat. No. 11,534,344, issued on Dec. 27, 2022, by Douglas Levinson, et al., which is stored in the United States Patent and Trademark Office (USPTO). |
| “Methods and Devices for Skin Tightening” Specification, Drawings and Prosecution History of U.S. Appl. No. 14/764,866, filed Jul. 30, 2015, now U.S. Pat. No. 10,543,127, issued on Jan. 28, 2020, by Douglas Levinson, et al., which is stored in the United States Patent and Trademark Office (USPTO). |
| “Methods and Devices for Skin Tightening” Specification, Drawings and Prosecution History of U.S. Appl. No. 15/905,421, filed Feb. 26, 2018, now U.S. Pat. No. 10,251,792, issued on Apr. 9, 2019, by Douglas Levinson, et al., which is stored in the United States Patent and Trademark Office (USPTO). |
| Canadian Office Action dated Oct. 4, 2022 issued in corresponding Canadian Application No. 2900505. |
| Israel Office Action dated Jan. 29, 2023 issued in corresponding Israel Application No. 291723, with English translation. |
| International Preliminary Report on Patentability dated Nov. 30, 2023 issued in International Application No. PCT/US2022/030236. |
| Alkilani et al. “Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum”, Pharmaceutics, vol. 7, No. 4 (Oct. 22, 2015), pp. 438-470. |
| Alsberg, E. et al., Engineering growing tissues, PNAS, 99(19):12025-12030 (2002). |
| Banzhaf, C. et al., Spatiotemporal Closure of Fractional Laser-Ablated Channels Imaged by Optical Coherence Tomography and Reflectance Confocal Microscopy, Lasers in Surgery and Medicine, 48:157-165 (2016). |
| Bedi, et al., The Effects of Pulse Energy Variations on the Dimensions of Microscopic Thermal Treatment Zones in Nonablative Fractional Resurfacing, Lasers in Surgery and Medicine, 2007, 39:145-155. |
| Bolshaya meditsinskaya entsiklopediya, M., 1976, vol. 3, p. 184. |
| Bolshaya meditsinskaya entsiklopediya, M., 1986, vol. 27, pp. 480-481. |
| Brannon, Heather. “Skin anatomy” Jul. 30, 2004 (updated Dec. 19, 2014), 4 pages. Originally Retrieved from Internet on Jan. 18, 2019. Retrieved again on Jun. 1, 2022. URL: https://web.archive.org/web/20150329121127/http://dermatology.about.com/CS/skinanatomy/a/anatomy.htm. |
| CEVC, Gregor, Drug delivery across the skin, Expert Opinion Investigational Drugs, 6(12):1887-937 (1997). |
| Chang, Te-Sheng, An updated review of tyrosinase inhibitors, Int J Mol Sci, 10(6):2440-2475 (2009). |
| Extended European Search Report dated Jul. 11, 2022 issued in related European Application No. 21210478.0. |
| International Preliminary Report on Patentability dated Aug. 25, 2015 issued in related International Application No. PCT/US2014/016483. |
| International Preliminary Report on Patentability dated Dec. 8, 2017 issued in related International Application No. PCT/US2017/052528. |
| International Preliminary Report on Patentability dated Feb. 17, 2015 issued in related International Application No. PCT/US2013/054955. |
| International Preliminary Report on Patentability dated Feb. 9, 2016 issued in related International Application No. PCT/US2014/050426. |
| International Preliminary Report on Patentability dated Jan. 6, 2015 issued in related International Application No. PCT/US2013/049445. |
| International Preliminary Report on Patentability dated Jul. 30, 2013 issued in related International Application No. PCT/US2012/022980. |
| International Preliminary Report on Patentability dated Jul. 30, 2013 issued in related International Application No. PCT/US2012/022987. |
| International Preliminary Report on Patentability dated Jul. 30, 2013 issued in related International Application No. PCT/US2012/022993. |
| International Preliminary Report on Patentability dated Jun. 21, 2016 issued in related International Application No. PCT/US2014/071443. |
| International Preliminary Report on Patentability dated Mar. 26, 2019 issued in related International Application No. PCT/US2017/052539. |
| International Preliminary Report on Patentability dated May 11, 2021 issued in related International Application No. PCT/US2019/060131. |
| International Preliminary Report on Patentability dated May 16, 2017 issued in related International Application No. PCT/US2015/060685. |
| International Preliminary Report on Patentability dated Nov. 13, 2012 issued in related International Application No. PCT/US2011/035613. |
| International Preliminary Report on Patentability dated Nov. 3, 2015 issued in related International Application No. PCT/US2014/036638. |
| International Preliminary Report on Patentability dated Nov. 4, 2014 issued in related International Application No. PCT/US2012/047716. |
| International Preliminary Report on Patentability dated Oct. 2, 2018 issued in related International Application No. PCT/US2017/024752. |
| International Preliminary Report on Patentability dated Oct. 5, 2010 issued in related International Application No. PCT/US2009/039114. |
| International Preliminary Report on Patentability dated Oct. 5, 2010 issued in related International Application No. PCT/US2009/039125. |
| International Report on Patentability dated Jan. 21, 2014 issued in related International Application No. PCT/US2012/047708. |
| International Search Report and Written Opinion dated Apr. 12, 2012 issued in related International Application No. PCT/US2012/022987. |
| International Search Report and Written Opinion dated Aug. 29, 2017 issued in related International Application No. PCT/US2017/024752. |
| Intemational Search Report and Written Opinion dated Aug. 9, 2012 issued in related International Application No. PCT/US2012/022980. |
| International Search Report and Written Opinion dated Dec. 19, 2013 issued in related International Application No. PCT/US2013/054955. |
| International Search Report and Written Opinion dated Feb. 2, 2016 issued in related International Application No. PCT/US2015/060685. |
| International Search Report and Written Opinion dated Feb. 4, 2015 issued in related International Application No. PCT/US2014/050426. |
| International Search Report and Written Opinion dated Jan. 12, 2012 issued by the Korean Intellectual Property Office as International Search Authority for related International Application No. PCT/US2011/035613. |
| International Search Report and Written Opinion dated Jan. 4, 2018 issued in related International Application No. PCT/US2017/052528. |
| International Search Report and Written Opinion dated Mar. 19, 2015 issued in related International Application No. PCT/US2014/071443. |
| International Search Report and Written Opinion dated Mar. 27, 2020 issued in related International Application No. PCT/US2019/060131. |
| International Search Report and Written Opinion dated May 17, 2012 issued in related International Application No. PCT/US2012/022993. |
| International Search Report and Written Opinion dated May 6, 2014 issued in related International Application No. PCT/US2014/016483. |
| International Search Report and Written Opinion dated Nov. 16, 2009 issued by the Korean Intellectual Property Office as Intemational Searching Authority for related International Application No. PCT/US2009/039114. |
| International Search Report and Written Opinion dated Nov. 16, 2009 issued in related International Application No. PCT/US2009/039125. |
| International Search Report and Written Opinion dated Nov. 22, 2017 issued in related International Application No. PCT/US2017/052539. |
| International Search Report and Written Opinion dated Oct. 18, 2012 issued in related International Application No. PCT/US2012/047708. |
| International Search Report and Written Opinion dated Oct. 18, 2013 issued in related International Application No. PCT/US2013/049445. |
| International Search Report and Written Opinion dated Oct. 2, 2014 issued in related International Application No. PCT/US2014/036638. |
| International Search Report and Written Opinion dated Oct. 25, 2012 issued in related International Application No. PCT/US2012/047716. |
| Czech, Z. et al., Pressure-sensitive adhesives for medical applications, Wide Spectra of Quality Control, Akyar, 309-332 (2011). |
| Dai, et al., Magnetically-Responsive Self Assembled Composites, Chemical Society Reviews, 2010, 39:4057-4066. |
| International Preliminary Report on Patentability dated Apr. 2, 2024 issued in International Application No. PCT/US2022/044862. |
| Number | Date | Country | |
|---|---|---|---|
| 20230310222 A1 | Oct 2023 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61766937 | Feb 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 14764866 | US | |
| Child | 16707122 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16707122 | Dec 2019 | US |
| Child | 17987190 | US |
